UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

[X]   QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2005

OR

[ ]   TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

001-32410
(Commission File Number)

CELANESE CORPORATION
(Exact Name of Registrant as Specified in its Charter)


Delaware 98-0420726
(State or Other Jurisdiction of
Incorporation or Organization)
(I.R.S. Employer Identification No.)
1601 West LBJ Freeway, Dallas, TX 75234-6034
(Address of Principal Executive Offices) (Zip Code)
(972) 443-4000
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes    [X]     No    [ ]

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes    [ ]     No    [X]

APPLICABLE ONLY TO CORPORATE ISSUERS

The number of outstanding shares of the registrant's Series A Common Stock, $ 0.0001 par value, as of August 5, 2005 was 158,544,801.

Exhibit index located on sequential page number 2.




CELANESE CORPORATION
Form 10-Q
For the Quarterly Period Ended June 30, 2005

TABLE OF CONTENTS


      Page
  Basis of Presentation   3  
  Market Industry and Data Forecasts   5  
  Special Note Regarding Forward-Looking Statements   5  
Part I Financial Information      
  Item 1. Financial Statements   6  
  Item 2. Management's Discussion and Analysis of Financial Condition
and Results of Operations
  48  
  Item 3. Quantitative and Qualitative Disclosures about Market Risk   73  
  Item 4. Controls and Procedures   73  
Part II Other Information      
  Item 1. Legal Proceedings   74  
  Item 2. Unregistered Sales of Equity Securities and Use of Proceeds   76  
  Item 3. Defaults Upon Senior Securities   76  
  Item 4. Submission of Matters to a Vote of Security Holders   76  
  Item 5. Other Information   76  
  Item 6. Exhibits   76  
  Signatures     78  
           
           
           
           
           

2




Basis of Presentation

In this Quarterly Report on Form 10-Q, the term "Celanese" refers to Celanese Corporation, a Delaware corporation, and not its subsidiaries. The terms the "Company," "we," "our" and "us" refer to Celanese and its subsidiaries on a consolidated basis. The term "BCP Crystal" refers to our subsidiary BCP Crystal US Holdings Corp., and not its subsidiaries. The term "Purchaser" refers to our subsidiary, Celanese Europe Holding GmbH & Co. KG, formerly known as BCP Crystal Acquisition GmbH & Co. KG, a German limited partnership ( Kommanditgesellschaft, KG ), and not its subsidiaries, except where otherwise indicated. The term "Original Shareholders" refers, collectively, to Blackstone Capital Partners (Cayman) Ltd. 1, Blackstone Capital Partners (Cayman) Ltd. 2, Blackstone Capital Partners (Cayman) Ltd. 3 and BA Capital Investors Sidecar Fund, L.P. The terms "Sponsor" and "Advisor" refer to certain affiliates of The Blackstone Group.

Celanese is a recently-formed company which does not have any independent external operations other than through the indirect ownership of CAG (as defined below) and CAC (as defined below), their consolidated subsidiaries, their non-consolidated subsidiaries, ventures and other investments. For accounting purposes, Celanese and its consolidated subsidiaries are referred to as the "Successor." See Note 1 to the Unaudited Interim Consolidated Financial Statements (as defined below) for additional information on the basis of presentation of the Successor.

Pursuant to a voluntary tender offer commenced in February 2004 (the "Tender Offer"), the Purchaser, an indirect wholly-owned subsidiary of Celanese, in April 2004 acquired approximately 84% of the ordinary shares of CAG (the "CAG Shares") outstanding. All references in this Quarterly Report to the outstanding ordinary shares of CAG exclude treasury shares. As of June 30, 2005, Celanese's indirect ownership of approximately 84% of the outstanding CAG Shares would equate to approximately 77% of the issued CAG Shares (including treasury shares). Pursuant to a mandatory offer commenced in September 2004 and continuing as of the date of this Quarterly Report, the Purchaser has acquired additional CAG Shares. As a result of these acquisitions, partially offset by the issuance of additional shares of CAG as a result of the exercise of options issued under a CAG stock option plan, as of June 30, 2005, we continue to own approximately 84% of the outstanding CAG Shares. The mandatory offer expires on October 1, 2005, unless further extended.

In October 2004, Celanese and certain of its subsidiaries completed an organizational restructuring (the "Restructuring") pursuant to which the Purchaser effected, by giving a corresponding instruction under the Domination Agreement (as defined below), the transfer of all of the shares of Celanese Americas Corporation ("CAC") from Celanese Holding GmbH, a wholly owned subsidiary of CAG, to BCP Caylux Holdings Luxembourg S.C.A. ("BCP Caylux") resulting in its ownership of 100% of the equity of CAC and indirectly, all of its assets, including subsidiary stock. Thereafter, BCP Caylux transferred certain assets, including its equity ownership interest in CAC, to BCP Crystal. In this Quarterly Report, the term "Domination Agreement" refers to the domination and profit and loss transfer agreement between CAG and the Purchaser, pursuant to which the Purchaser became obligated on October 1, 2004 to offer to acquire all outstanding CAG Shares from the minority shareholders of CAG in return for payment of fair cash compensation in accordance with German law.

Celanese AG is incorporated as a stock corporation ( Aktiengesellschaft , AG) organized under the laws of the Federal Republic of Germany. As used in this document, the term "CAG" refers to (i) prior to the Restructuring, Celanese AG and CAC, their consolidated subsidiaries, their non-consolidated subsidiaries, ventures and other investments, and (ii) following the Restructuring, Celanese AG, its consolidated subsidiaries, its non-consolidated subsidiaries, ventures and other investments, except that with respect to shareholder and similar matters where the context indicates, "CAG" refers to Celanese AG. For accounting purposes, "Predecessor" refers to CAG and its subsidiaries.

Following the transfer of CAC to BCP Crystal, (1) BCP Crystal Holdings Ltd. 2 contributed substantially all of its assets and liabilities (including all outstanding capital stock of BCP Caylux) to BCP Crystal and (2) BCP Crystal assumed certain obligations of BCP Caylux, including all rights and obligations of BCP Caylux under the senior credit facilities, the floating rate term loan and the notes.

3




BCP Crystal Holdings Ltd. 2 reorganized as a Delaware limited liability company and changed its name to Celanese Holdings LLC. Blackstone Crystal Holdings Capital Partners (Cayman) IV Ltd. reorganized as a Delaware corporation and changed its name to Celanese Corporation. BCP Crystal, at its discretion, may subsequently cause the liquidation of BCP Caylux.

As a result of these transactions, BCP Crystal holds 100% of CAC's equity and, indirectly, all equity owned by CAC in its subsidiaries. In addition, BCP Crystal holds, indirectly, all of the outstanding common stock of CAG held by the Purchaser and all of the wholly owned subsidiaries of Celanese that guarantee BCP Caylux's obligations under the senior credit facilities and guarantee the senior subordinated notes issued on June 8, 2004 and July 1, 2004 on an unsecured senior subordinated basis. See Notes 3 and 9 to the Unaudited Interim Consolidated Financial Statements (as defined below).

As of the date of this Quarterly Report, Celanese has two classes of common stock, Series A common stock and Series B common stock, and convertible perpetual preferred stock. In January 2005, Celanese completed an initial public offering of 50,000,000 shares of Series A common stock. The Series A common stock is currently held by public shareholders, the Original Shareholders and certain directors, officers and employees of the Company. No shares of Series B common stock are currently outstanding. All of the shares of Series B common stock outstanding were automatically converted into Series A common stock on April 7, 2005 following the payment on that date of a special Series B common stock cash dividend declared on March 8, 2005 to the then holders of the outstanding shares of Series B common stock. Except for (i) the special Series A common stock dividend which we paid to the holders of outstanding shares of Series B common stock on March 9, 2005 and a special cash dividend which we paid to the holders of outstanding shares of Series B common stock on April 7, 2005, (ii) the convertibility of Series B common stock into Series A common stock and (iii) the right of the Series B common stock to consent to any changes to our governing documents that would adversely affect the Series B common stock, shares of Series A common stock and shares of Series B common stock are identical, including with respect to voting rights. Holders of the common stock are entitled to receive, when, as and if, declared by the Celanese board of directors, out of funds legally available therefor, cash dividends at the rate per annum of 1% of the $16.00 initial public offering price per share of our Series A common stock (or $0.16 per share), payable on a quarterly basis. The initial quarterly dividend payment was made on August 11, 2005. As used in this Quarterly Report, the term "common stock" means, collectively, the Series A common stock and the Series B common stock, and the term "preferred stock" means the convertible perpetual preferred stock, in each case unless otherwise specified.

Concurrently with the initial public offering of its Series A common stock, Celanese offered 9,600,000 shares of its preferred stock. Holders of the preferred stock are entitled to receive, when, as and if, declared by the Celanese board of directors, out of funds legally available therefor, cash dividends at the rate of 4.25% per annum of liquidation preference, payable quarterly in arrears. The initial quarterly dividend payment was made on May 1, 2005. Dividends on the preferred stock are cumulative from the date of initial issuance. The preferred stock is convertible, at the option of the holder, at any time, into shares of our Series A common stock at a conversion rate of 1.25 shares of Series A common stock for each share of preferred stock, subject to adjustments.

The unaudited interim consolidated financial statements of the Successor for the three and six months ended June 30, 2005 and the three months ended June 30, 2004 as well as the unaudited interim consolidated financial statements of the Predecessor for the three months ended March 31, 2004 contained in this Quarterly Report (collectively, the "Unaudited Interim Consolidated Financial Statements") were prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") for all periods presented. The Unaudited Interim Consolidated Financial Statements and other financial information included in this Quarterly Report, unless otherwise specified, have been presented to separately show the effects of discontinued operations. The results of the Successor are not comparable to the results of the Predecessor due to the differences in the basis of presentation of purchase accounting as compared to historical cost.

CAG is a foreign private issuer and previously filed its consolidated financial statements as of December 31, 2003 and 2002 in its Annual Report on Form 20-F. CAG changed its fiscal year end to

4




September 30 and filed its consolidated financial statements as of September 30, 2004 and for the nine months then ended in its 2004 Annual Report on Form 20-F. In accordance with German law, the reporting currency of the CAG consolidated financial statements is the euro. As a result of the Purchaser's acquisition of voting control of CAG, the financial statements of CAG contained in this document are reported in U.S. dollars to be consistent with our reporting requirements. For CAG's reporting requirements, the euro continues to be the reporting currency.

In the preparation of other information included in this document, euro amounts have been translated into U.S. dollars at the applicable historical rate in effect on the date of the relevant event or period. For purposes of prospective information, euro amounts have been translated into U.S. dollars using the rate in effect on June 30, 2005. Our inclusion of this information is not meant to suggest that the euro amounts actually represent such dollar amounts or that such amounts could have been converted into U.S. dollars at any particular rate, if at all.

Market Industry and Data Forecasts

This document includes industry data and forecasts that Celanese has prepared based, in part, upon industry data and forecasts obtained from industry publications and surveys and internal company surveys. Third-party industry publications and surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable.

AO Plus™, BuyTiconaDirect™, CelActiv ® , Celanex ® , Celcon ® , Celstran ® , Celvolit ® , Compel ® , GUR ® , Hoecat ® , Hostaform ® , Impet ® , Impet-HI ® , Mowilith ® , Nutrinova ® DHA, Riteflex ® , Sunett ® , Topas ® , Vandar ® , VAntage™, Vectra ® , Vectran ® , Vinamul ® , Elite ® , Duroset ® and certain other products and services that may be named in this document are registered trademarks and service marks of CAG. Acetex ® is a registered trademark of Acetex Corporation, an indirect wholly owned subsidiary of Celanese. Fortron ® is a registered trademark of Fortron Industries, a venture of Celanese.

Special Note Regarding Forward-Looking Statements

Investors are cautioned that the forward-looking statements contained in this Quarterly Report involve both risk and uncertainty. Many important factors could cause actual results to differ materially from those anticipated by these statements. Many of these factors are macroeconomic in nature and are, therefore, beyond our control. See "Management's Discussion and Analysis of Financial Condition and Results of Operations—Forward-Looking Statements May Prove Inaccurate."

5




PART I – FINANCIAL INFORMATION

Item 1.    Financial Statements

INDEX TO THE UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS


  PAGE
CELANESE CORPORATION UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS      
Unaudited Consolidated Statements of Operations for the three months ended June 30, 2005 and 2004   7  
Unaudited Consolidated Statements of Operations for the six months ended June 30, 2005 and the three months ended June 30, 2004 and March 31, 2004   8  
Unaudited Consolidated Balance Sheets as of June 30, 2005 and December 31, 2004   9  
Unaudited Consolidated Statements of Shareholders' Equity (Deficit) for the six months ended June 30, 2005 and the three months ended June 30, 2004 and March 31, 2004   10  
Unaudited Consolidated Statements of Cash Flows for the six months ended June 30, 2005 and the three months ended June 30, 2004 and March 31, 2004   11  
Notes to the Unaudited Interim Consolidated Financial Statements   13  

6




CELANESE CORPORATION AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS


  Successor Successor
  Three Months Ended
June 30, 2005
Three Months Ended
June 30, 2004
  (in $ millions, except for share and per share data)
Net sales   1,517     1,229  
Cost of sales   (1,175   (1,058
Selling, general and administrative expenses   (136   (125
Research and development expenses   (23   (22
Special charges:            
Insurance recoveries associated with plumbing cases   4     2  
Restructuring, impairment and other special charges   (31   (1
Foreign exchange gain (loss), net   (1    
Gain (loss) on disposition of assets, net   (3    
Operating profit   152     25  
Equity in net earnings of affiliates.   12     18  
Interest expense   (68   (130
Interest income   9     7  
Other income (expense), net .   18     (24
Earnings (loss) from continuing operations before tax and minority interests   123     (104
Income tax provision   (43   (10
Earnings (loss) from continuing operations before minority interests   80     (114
Minority interests   (13   (10
Earnings (loss) from continuing operations   67     (124
Earnings (loss) from discontinued operations       (1
Net earnings (loss) .   67     (125
Cumulative undeclared preferred stock dividend   (2    
Net earnings (loss) available to common shareholders   65     (125
Earnings (loss) per common share — basic:      
Continuing operations   0.41     (1.25
Discontinued operations       (0.01
Net earnings (loss) available to common shareholders   0.41     (1.26
Earnings (loss) per common share — diluted:      
Continuing operations .   0.39     (1.25
Discontinued operations       (0.01
Net earnings (loss) available to common shareholders   0.39     (1.26
Weighted average shares — basic:   158,530,397     99,377,884  
Weighted average shares — diluted:   170,530,397     99,377,884  

See the accompanying notes to the unaudited interim consolidated financial statements.

7




CELANESE CORPORATION AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS


  Successor Predecessor
  Six Months Ended
June 30, 2005
Three Months Ended
June 30, 2004
Three Months Ended
March 31, 2004
  (in $ millions, except for share and per share data)
Net sales   3,026     1,229     1,243  
Cost of sales   (2,300   (1,058   (1,002
Selling, general and administrative expenses   (297   (125   (137
Research and development expenses   (46   (22   (23
Special charges:            
Insurance recoveries associated with plumbing cases   4     2      
Restructuring, impairment and other special charges   (69   (1   (28
Foreign exchange gain (loss), net   2          
Gain (loss) on disposition of assets, net   (2       (1
Operating profit   318     25     52  
Equity in net earnings of affiliates.   27     18     12  
Interest expense   (244   (130   (6
Interest income   24     7     5  
Other income (expense), net .   21     (24   9  
Earnings (loss) from continuing operations before tax and minority interests   146     (104   72  
Income tax provision   (51   (10   (17
Earnings (loss) from continuing operations before minority interests   95     (114   55  
Minority interests   (38   (10    
Earnings (loss) from continuing operations   57     (124   55  
Earnings (loss) from discontinued operations:            
Gain (loss) from operation of discontinued operations .           (5
Gain (loss) on disposal of discontinued operations.       (1   14  
Income tax benefit (expense)           14  
Earnings (loss) from discontinued operations       (1   23  
Net earnings (loss) .   57     (125   78  
Cumulative declared and undeclared preferred stock dividend   (4        
Net earnings (loss) available to common shareholders   53     (125   78  
Earnings (loss) per common share — basic:            
Continuing operations   0.35     (1.25   1.12  
Discontinued operations       (0.01   0.46  
Net earnings (loss) available to common shareholders   0.35     (1.26   1.58  
Earnings (loss) per common share — diluted:            
Continuing operations .   0.35     (1.25   1.11  
Discontinued operations       (0.01   0.46  
Net earnings (loss) available to common shareholders   0.35     (1.26   1.57  
Weighted average shares — basic:   150,182,788     99,377,884     49,321,468  
Weighted average shares — diluted:   162,273,928     99,377,884     49,712,421  

See the accompanying notes to the unaudited interim consolidated financial statements.

8




CELANESE CORPORATION AND SUBSIDIARIES
UNAUDITED CONSOLIDATED BALANCE SHEETS


  Successor
  As of
June 30, 2005
As of
December 31, 2004
  (in $ millions)
ASSETS      
Current assets:      
Cash and cash equivalents   959     838  
Receivables      
Trade receivables, net — third party and affiliates, net of allowance for doubtful accounts of $22 million as of June 30, 2005 and December 31, 2004:   955     866  
Other receivables   523     670  
Inventories   586     618  
Deferred income taxes   75     71  
Other assets   106     86  
Assets of discontinued operations   3     2  
Total current assets   3,207     3,151  
Investments   543     600  
Property, plant and equipment, net of accumulated depreciation of $563 million and $446 million as of June 30, 2005 and December 31, 2004, respectively   1,756     1,702  
Deferred income taxes   36     54  
Other assets   652     756  
Goodwill   813     747  
Intangible assets, net   389     400  
Total assets   7,396     7,410  
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)      
Current liabilities:      
Short-term borrowings and current installments of long-term debt — third party and affiliates   140     144  
Accounts payable and accrued liabilities:      
Trade payables — third party and affiliates   682     722  
Other current liabilities   739     888  
Deferred income taxes   14     20  
Income taxes payable   230     214  
Liabilities of discontinued operations   7     7  
Total current liabilities   1,812     1,995  
Long-term debt   3,253     3,243  
Deferred income taxes   227     256  
Benefit obligations   1,003     1,000  
Other liabilities   452     510  
Minority interests   523     518  
Commitments and contingencies      
Shareholders' equity (deficit):      
Preferred stock, $0.01 par value, 100,000,000 shares authorized and 9,600,000 issued and outstanding as of June 30, 2005        
Series A common stock, $0.0001 par value, 400,000,000 shares authorized and 158,544,801 issued and outstanding as of June 30, 2005. Series B common stock, $0.0001 par value, 100,000,000 shares authorized and 99,377,884 issued as of December 31, 2004        
Additional paid-in capital   350     158  
Retained earnings (deficit)   (196   (253
Accumulated other comprehensive income (loss), net   (28   (17
Total shareholders' equity (deficit)   126     (112
Total liabilities and shareholders' equity (deficit)   7,396     7,410  

See the accompanying notes to the unaudited interim consolidated financial statements.

9




CELANESE CORPORATION AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (DEFICIT)


  Preferred
Stock
Common
Stock
Additional
Paid-in
Capital
Retained
Earnings
(Deficit)
Accumulated
Other
Comprehensive
Income (Loss), Net
Treasury
Stock
Total
Shareholders'
Equity
(Deficit)
  (in $ millions)
Predecessor                                          
Balance at December 31, 2003       150     2,714     25     (198   (109   2,582  
Comprehensive income (loss), net of tax:                                          
Net earnings (loss)               78             78  
Other comprehensive income (loss):                                          
Unrealized gain (loss) on securities                   7         7  
Foreign currency translation                   (46       (46
Other comprehensive income (loss)                   (39       (39
Comprehensive income (loss)                           39  
Amortization of deferred compensation.           1                 1  
Balance at March 31, 2004       150     2,715     103     (237   (109   2,622  
 
Successor
Contributed capital           641                 641  
Comprehensive income (loss), net of tax:
Net earnings (loss)               (125           (125
Other comprehensive income (loss):
Unrealized gain (loss) on securities                   (7       (7
Foreign currency translation                            
Unrealized gain (loss) on derivative contracts                   (16       (16
Other comprehensive income (loss)                   (23       (23
Comprehensive income (loss)                           (148
Indemnification of demerger liability           1                 1  
Balance at June 30, 2004           642     (125   (23       494  
 
Successor                                          
Balance at December 31, 2004 .           158     (253   (17       (112
Comprehensive income (loss), net of tax:                                          
Net earnings (loss)               57             57  
Other comprehensive income (loss):                                          
Unrealized gain (loss) on securities                           3           3  
Foreign currency translation                   (4       (4
Unrealized gain (loss) on derivative contracts                   (10       (10
Other comprehensive income (loss)                   (11       (11
Comprehensive income (loss)                           46  
Indemnification of demerger liability           2                 2  
Preferred stock dividend               (3                     (3
Net proceeds from issuance of common stock           752                 752  
Net proceeds from issuance of preferred stock           233                 233  
Net proceeds from issuance of discounted common stock           12                 12  
Distribution to Series B shareholders           (804               (804
Balance at June 30, 2005           350     (196   (28       126  

See the accompanying notes to the unaudited interim consolidated financial statements.

10




CELANESE CORPORATION AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS


  Successor Predecessor
  Six Months
Ended
June 30, 2005
Three Months
Ended
June 30, 2004
Three Months
Ended
March 31, 2004
  (in $ millions)
Operating activities from continuing operations:            
Net earnings (loss)   57     (125   78  
(Earnings) loss from discontinued operations, net       1     (23
Adjustments to reconcile net earnings (loss) to net cash provided by (used in) operating activities:                           
Special charges, net of amounts used   3     (20   20  
Stock based compensation       1     2  
Depreciation   100     68     69  
Amortization of intangible and other assets   30     3     3  
Amortization of deferred financing fees   35     73      
Premium on early redemption of debt   74          
Change in equity of affiliates   19     (12   3  
Deferred income taxes   (18   (19   (12
(Gain) loss on disposition of assets, net   2          
(Gain) loss on foreign currency, net   42     19     (26
Minority interest   38     10      
Changes in operating assets and liabilities:                  
Trade receivables, net — third party and affiliates   (115   6     (89
Other receivables   53     (30   (42
Prepaid expenses   (21   20     14  
Inventories   26     49     (11
Trade payables — third party and affiliates   (30   (18   (6
Benefit obligations and other liabilities   (159   (138   (118
Income taxes payable   42     22     38  
Other, net   12     (17   (7
Net cash provided by (used in) operating activities   190     (107   (107
Investing activities from continuing operations:               
Capital expenditures on property, plant and equipment   (86   (50   (44
Acquisition of CAG, net of cash acquired   (6   (1,531    
Fees associated with acquisitions   (10   (67    
Acquisition of Vinamul   (208        
Proceeds from sale of assets   14     1      
Net proceeds from disposal of discontinued operations   75         139  
Proceeds from sale of marketable securities   141     27     42  
Purchases of marketable securities   (59   (28   (42
Other, net   1     (1   1  
Net cash provided by (used in) investing activities   (138   (1,649   96  

11




CELANESE CORPORATION AND SUBSIDIARIES
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)


  Successor Predecessor
  Six Months
Ended
June 30, 2005
Three Months
Ended
June 30, 2004
Three Months
Ended
March 31, 2004
  (in $ millions)
Financing activities from continuing operations:            
Initial capitalization       641      
Issuance of mandatorily redeemable preferred stock       200      
Borrowings under bridge loans       1,565      
Repayment of bridge loans       (1,565    
Proceeds from issuance of senior subordinated notes       1,244      
Redemption of senior subordinated notes, including related premium   (572        
Proceeds from floating rate term loan       350      
Repayment of floating rate term loan, including related premium   (354        
Borrowings under term loan facility   1,135     389      
Proceeds from issuance of common stock, net   752          
Proceeds from issuance of preferred stock, net   233          
Proceeds from issuance of discounted common stock   12          
Redemption of senior discount notes, including related premium   (207        
Distribution to Series B shareholders   (804        
Short-term borrowings (repayments), net   (26   7     (16
Proceeds (payments) from other long term debt, net   9     (177   (27
Issuance of preferred stock by consolidated subsidiary            15      
Fees associated with financings   (7   (170    
Dividend payments   (3   (1    
Net cash provided by (used in) financing activities   168     2,498     (43
Exchange rate effects on cash .   (99   (26   (1
Net increase (decrease) in cash and cash equivalents .   121     716     (55
Cash and cash equivalents at beginning of period   838         148  
Cash and cash equivalents at end of period   959     716     93  
Net cash provided by (used in) discontinued operations:                  
Operating activities   (75       (139
Investing activities   75         139  
Financing activities            
Net cash provided by (used in) discontinued operations            

See the accompanying notes to the unaudited interim consolidated financial statements.

12




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS

1.     Description of the Company and Basis of Presentation

Description of the Company

Celanese Corporation and its subsidiaries (collectively the "Company" or the "Successor") is a global industrial chemicals company, primarily comprising the former business of Celanese AG and its subsidiaries ("CAG" or the "Predecessor"). The Company's business involves processing chemical raw materials, such as ethylene and propylene, and natural products, including natural gas and wood pulp, into value-added chemicals and chemical-based products.

Basis of Presentation

The results of operations and cash flows and related disclosures for periods prior to April 1, 2004 (a convenience date for the April 6, 2004 acquisition date), the effective date of the acquisition of CAG (the "Effective Date"), are presented as those of the Predecessor. The financial position, results of operations and cash flows and related disclosures subsequent to the Effective Date, are presented as those of the Successor.

The unaudited interim consolidated financial statements of the Successor as of and for the three and six months ended June 30, 2005, for the three months ended June 30, 2004 and as of December 31, 2004 reflect the acquisition of CAG under the purchase method of accounting in accordance with Financial Accounting Standards Board ("FASB") Statement of Financial Accounting Standards ("SFAS") No. 141, Business Combinations .

In the opinion of management, the unaudited interim consolidated financial statements contain all adjustments (consisting only of normal recurring adjustments) necessary for a fair presentation of the financial position, results of operations, and cash flows of the Company and the Predecessor. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") have been condensed or omitted in accordance with rules and regulations of the Securities and Exchange Commission ("SEC"). These unaudited interim consolidated financial statements should be read in conjunction with the Celanese Corporation and Subsidiaries consolidated financial statements as of and for the nine months ended December 31, 2004, as filed with the SEC on Form 10-K.

Operating results for the three and six months ended June 30, 2005 and for the three months ended June 30, 2004 and March 31, 2004 are not necessarily indicative of the results to be expected for the entire year. The results of the Successor are not comparable to the results of the Predecessor due to the difference in the basis of presentation of purchase accounting as compared to historical cost.

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues, expenses and allocated charges during the reporting period. The more significant estimates pertain to purchase accounting, allowance for doubtful accounts, inventory allowances, impairments of intangible assets and other long-lived assets, restructuring costs and other special charges, income taxes, pension and other postretirement benefits, asset retirement obligations, environmental liabilities and loss contingencies, among others. Actual results could differ from those estimates.

The Company has reclassified certain prior period amounts to conform to the current period's presentation.

2.     Acquisition of Celanese AG (the "Acquisition")

On April 6, 2004, Celanese Europe Holding GmbH & Co. KG (the "Purchaser"), an indirect wholly owned subsidiary of the Successor, acquired approximately 84% of the Celanese AG ordinary

13




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

shares, excluding treasury shares ("CAG Shares"), pursuant to a voluntary tender offer commenced in February 2004. The CAG Shares were acquired at a price of €32.50 per share or an aggregate purchase price of $1,693 million, including direct acquisition costs of approximately $69 million. During the nine months ended December 31, 2004 and the six months ended June 30, 2005, the Purchaser acquired additional CAG Shares for a purchase price of $33 million and $6 million, respectively. As of June 30, 2005 and December 31, 2004, the Purchaser's ownership percentage remained at approximately 84%. The additional CAG Shares were acquired pursuant to a mandatory offer commenced in September 2004 that will expire on October 1, 2005, unless further extended.

Pro forma information

The following pro forma information for the six months ended June 30, 2004 was prepared as if the Acquisition had occurred as of the beginning of such period:


  Six Months Ended
June 30, 2004
  (in $ millions)
Net sales   2,472  
Operating profit   115  
Net earnings (loss)   (31

Pro forma adjustments include adjustments for (1) purchase accounting, including (i) the application of purchase accounting to pension and other postretirement obligations (ii) the application of purchase accounting to property, plant and equipment and intangible assets, (2) adjustments for items directly related to the transaction, including (i) the impact of the additional pension contribution, (ii) fees incurred by the Company related to the Acquisition, and (iii) adjustments to interest expense to reflect the Company's new capital structure, and (3) corresponding adjustments to income tax expense.

The pro forma information is not necessarily indicative of the results that would have occurred had the Acquisition occurred as of the beginning of the period presented, nor is it necessarily indicative of future results.

3.     Domination Agreement and Organizational Restructuring

Domination Agreement

On October 1, 2004, a domination and profit and loss transfer agreement (the "Domination Agreement") between Celanese AG and the Purchaser became operative. When the Domination Agreement became operative, the Purchaser became obligated to offer to acquire all outstanding CAG Shares from the minority shareholders of Celanese AG in return for payment of fair cash compensation. The amount of this fair cash compensation has been determined to be €41.92 per share, plus interest, in accordance with applicable German law. The Purchaser may elect, or be required, to pay a purchase price in excess of €41.92 to acquire the remaining outstanding CAG Shares. Any minority shareholder who elects not to sell its shares to the Purchaser will be entitled to remain a shareholder of CAG and to receive from the Purchaser a gross guaranteed fixed annual payment on its shares of €3.27 per CAG Share less certain corporate taxes in lieu of any future dividend. Beginning October 1, 2004, taking into account the circumstances and the tax rates at the time of entering into the Domination Agreement, the net guaranteed fixed annual payment would be €2.89 per share for a full fiscal year. The net guaranteed fixed annual payment may, depending on applicable corporate tax rates, in the future be higher, lower or the same as €2.89 per share. For the three and six months ended June 30, 2005, a charge of $7 million and $15 million, respectively was recorded in Other income (expense), net for the anticipated guaranteed payment.

14




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

Beginning October 1, 2004, under the terms of the Domination Agreement, the Purchaser, as the dominating entity, among other things, is required to compensate Celanese AG for any statutory annual loss incurred by Celanese AG, the dominated entity, on a non-consolidated basis, at the end of the fiscal year when the loss was incurred. This obligation to compensate Celanese AG for annual losses will apply during the entire term of the Domination Agreement.

There is no assurance that the Domination Agreement will remain operative in its current form. If the Domination Agreement ceases to be operative, the Company will not be able to directly give instructions to the Celanese AG board of management. The Domination Agreement cannot be terminated by the Purchaser in the ordinary course until September 30, 2009. However, irrespective of whether a domination agreement is in place between the Company and Celanese AG, under German law Celanese AG is effectively controlled by the Company because of the Company's approximate 84% ownership of the outstanding CAG Shares. The Company does have the ability, through a variety of means, to utilize its controlling rights to, among other things, (1) cause a domination agreement to become operative; (2) use its ability, through its approximately 84% voting power at any shareholders' meetings of Celanese AG, to elect the shareholder representatives on the supervisory board and to thereby effectively control the appointment and removal of the members of the Celanese AG board of management; and (3) effect all decisions that an approximately 84% majority shareholder is permitted to make under German law. The controlling rights of the Company constitute a controlling financial interest for accounting purposes and result in the Company being required to consolidate CAG as of the date of acquisition.

Organizational Restructuring

In October 2004, Celanese Corporation and certain of its subsidiaries completed an organizational restructuring (the "Organizational Restructuring") pursuant to which the Purchaser effected, by giving a corresponding instruction under the Domination Agreement, the transfer of all of the shares of Celanese Americas Corporation ("CAC") from Celanese Holding GmbH, a wholly owned subsidiary of Celanese AG, to BCP Caylux Holdings Luxembourg S.C.A ("BCP Caylux"), which resulted in BCP Caylux owning 100% of the equity of CAC and, indirectly, all of its assets, including subsidiary stock. This transfer was affected by CAG selling all outstanding shares in CAC for a €291 million note. This note eliminates in consolidation.

Following the transfer of CAC to BCP Caylux, (1) Celanese Holdings contributed substantially all of its assets and liabilities (including all outstanding capital stock of BCP Caylux) to BCP Crystal US Holdings Corp. ("BCP Crystal") in exchange for all outstanding capital stock of BCP Crystal and (2) BCP Crystal assumed certain obligations of BCP Caylux, including all rights and obligations of BCP Caylux under the senior credit facilities, the floating rate term loan and the senior subordinated notes. BCP Crystal, at its discretion, may subsequently cause the liquidation of BCP Caylux.

As a result of these transactions, BCP Crystal holds 100% of CAC's equity and, indirectly, all equity owned by CAC in its subsidiaries. In addition, BCP Crystal holds, indirectly, all of the outstanding common stock of Celanese AG held by the Purchaser and all of the wholly owned subsidiaries of the Company that guarantee BCP Caylux's obligations under the senior credit facilities guarantee the senior subordinated notes issued on June 8, 2004 and July 1, 2004 (see Note 9) on an unsecured senior subordinated basis.

4.     Initial Public Offering and Concurrent Financings

In January 2005, the Company completed an initial public offering of 50,000,000 shares of Series A common stock and received net proceeds of $752 million after deducting underwriters' discounts and offering expenses of $48 million. Concurrently, the Company received net proceeds of $233 million from the offering of 9,600,000 shares of convertible perpetual preferred stock after deducting

15




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

underwriters' discounts and offering expenses of $7 million. A portion of the proceeds of the share offerings were used to redeem $188 million of senior discount notes and $521 million of senior subordinated notes, excluding early redemption premiums of $19 million and $51 million, respectively.

Subsequent to the closing of the initial public offering, the Company borrowed an additional $1,135 million under the amended and restated senior credit facilities; a portion of which was used to repay a $350 million floating rate term loan, which excludes a $4 million early redemption premium, and $200 million of which was used as the primary financing for the February 2005 acquisition of the Vinamul business (see Notes 6 and 9). Additionally, the amended and restated senior credit facilities included a $242 million delayed draw term loan. The delayed draw facility expired unutilized in July 2005.

On April 7, 2005, the Company used the remaining proceeds of the initial public offering and concurrent financings to pay a special cash dividend to holders of the Company's Series B common stock of $804 million, which was declared March 8, 2005. In addition, on March 9, 2005, the Company issued a 7,500,000 Series A common stock dividend to the Original Shareholders of its Series B common stock which was declared on March 8, 2005. Upon payment of the $804 million dividend, all of the outstanding shares of Series B common stock converted automatically to shares of Series A common stock.

5.     Accounting Changes and New Accounting Pronouncements

Accounting Changes

During 2004, the Predecessor changed its inventory valuation method of accounting for its US subsidiaries from the LIFO method to the FIFO method to conform to the Successor's accounting policy. The Predecessor's financial statements have been restated to reflect this change.

In March 2004, the Emerging Issues Task Force ("EITF") reached a consensus on Issue No. 03-01, Other than Temporary Impairment , which outlines the basic model to be used to evaluate whether an investment is impaired and sets the disclosure requirements for such investments. EITF Issue No. 03-1 is to be applied prospectively in periods beginning after June 15, 2004. The Company has applied the provisions of EITF Issue No. 03-01 in the current reporting period with no material impact on the Company's financial position or results of operations and cash flows for the six months ended June 30, 2005.

On December 8, 2003, the Medicare Prescription Drug, Improvement and Modernization Act of 2003 (the "Medicare Act") was signed into law. The Act introduces a prescription drug benefit under Medicare ("Medicare Part D") as well as a federal subsidy to sponsors of retiree health care benefit plans that provide a benefit that is at least actuarially equivalent to Medicare Part D. As of March 31, 2004, as permitted by FASB Staff Position ("FSP") 106-1, Accounting and Disclosure Requirements Related to the Medicare Prescription Drug, Improvement and Modernization Act of 2003, the Company deferred accounting for the effects of the Act in the measurement of its Accumulated Postretirement Benefit Obligation (APBO) and the effect to net periodic postretirement benefit costs. Specific guidance with respect to accounting for the effects of the Act was issued in FSP No. 106-2, Accounting and Disclosure Requirements Related to the Medicare Prescription Drug, Improvement and Modernization Act of 2003, and the Company has adopted the provisions of FSP No. 106-2 as of the Effective Date, and included any impact in the overall measurement of the liabilities of the U.S. postretirement medical plans in purchase accounting.

In March 2005, the FASB issued FSP No. FIN 46(R)-5, Implicit Variable Interests under FASB Interpretation No. 46 (revised December 2003) . FSP FIN 46(R)-5 addresses whether a reporting enterprise should consider whether it holds an implicit interest in a variable interest entity or potential

16




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

variable interest entity when specific conditions exist. The provisions of FSP FIN 46(R)-5 are applicable for reporting periods beginning after March 3, 2005 (the Company's fiscal quarter ending June 30, 2005). FSP FIN 46(R)-5 did not have a material impact on the Company's consolidated financial statements for the three months ended June 30, 2005.

Recent Accounting Pronouncements

In May 2005, the FASB issued Statement of Financial Accounting Standards No. 154, Accounting Changes and Error Corrections-A Replacement of APB Opinion No. 20 and FASB Statement No. 3 ("SFAS No. 154"). SFAS No. 154 requires retrospective application to prior periods financial statements for changes in accounting principle, unless it is impracticable to determine either the period-specific effects or the cumulative effect of the change. SFAS No. 154 also requires that retrospective application of a change in accounting principle be limited to the direct effects of the change. Indirect effects of a change in accounting principle, such as a change in non-discretionary profit-sharing payments resulting from an accounting change, should be recognized in the period of the accounting change. SFAS No. 154 also requires that a change in depreciation, amortization, or depletion method for long-lived non-financial assets be accounted for as a change in accounting estimate affected by a change in accounting principle. SFAS No. 154 is effective for accounting changes and corrections of errors made in fiscal years beginning after December 15, 2005. Early adoption is permitted for accounting changes and corrections of errors made in fiscal years beginning after the date this Statement is issued. The Company is required to adopt the provision of SFAS No. 154, as applicable, beginning in the fiscal year ended December 31, 2006.

In June 2005, the FASB s Emerging Issues Task Force reached a consensus on Issue No. 05-6, Determining the Amortization Period for Leasehold Improvements ("EITF Issue No. 05-6"). The guidance requires that leasehold improvements acquired in a business combination or purchased subsequent to the inception of a lease be amortized over the lesser of the useful life of the assets or a term that includes renewals that are reasonably assured at the date of the business combination or purchase. The guidance is effective prospectively for leasehold improvements acquired in periods beginning after June 29, 2005.

In March 2005, FASB issued Interpretation No. 47, Accounting for Conditional Asset Retirement Obligations – an interpretation of FASB Statement No. 143 ("FIN No. 47"). FIN No. 47 provides guidelines as to when a company is required to record a conditional asset retirement obligation. In general, an entity is required to recognize a liability for the fair value of a conditional asset retirement obligation if the fair value of the liability can be reasonably estimated. The fair value of a liability for the conditional asset retirement obligation should be recognized when incurred – generally upon acquisition, construction, or development and (or) through the normal operation of the asset. FIN No. 47 is effective no later than the end of fiscal years ending after December 15, 2005 (December 31, 2005, for calendar-year enterprises). The Company is still assessing the impact of FIN No. 47 on its future results of operations and financial position.

In December 2004, the FASB issued SFAS No. 153, Exchanges of Nonmonetary Assets, an amendment of APB Opinion No. 29, Accounting for Nonmonetary Transactions . The amendments made by SFAS No. 153 are based on the principle that exchanges of nonmonetary assets should be measured based on the fair value of the assets exchanged. Further, the amendments eliminate the narrow exception for nonmonetary exchanges of similar productive assets and replace it with a broader exception for exchanges of nonmonetary assets that do not have commercial substance. The statement is effective for nonmonetary asset exchanges occurring in fiscal periods beginning after June 15, 2005. Earlier application is permitted for nonmonetary asset exchanges occurring in fiscal periods beginning after the date of issuance. The provisions of this statement shall be applied prospectively. The Company is currently evaluating the potential impact of this statement.

17




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

In December 2004, the FASB revised SFAS No. 123, Accounting for Stock Based Compensation ("SFAS No. 123R"), which requires that the cost from all share-based payment transactions be recognized in the financial statements. In March 2005, the SEC issued Staff Accounting Bulletin No. 107 ("SAB 107") regarding the SEC's interpretation of SFAS 123R and the valuation of share-based payments for public companies. The SEC has deferred SFAS No. 123R until the first annual period beginning after June 15, 2005. Accordingly, the Company intends to comply with SFAS No. 123R beginning with the fiscal year commencing January 1, 2006. The Company is currently evaluating the potential impact of SFAS No. 123R, although it is anticipated that the adoption will have a negative impact on its results of operations.

In November 2004, the FASB issued SFAS No. 151, Inventory Costs, amendment to ARB No. 43 Chapter 4 ("SFAS No. 151"), which clarifies the accounting for abnormal amounts of idle facility expense, freight, handling costs, and wasted material (spoilage). SFAS No. 151 is effective for fiscal years beginning after June 15, 2005. The Company is in the process of assessing the impact of SFAS No. 151 on its future results of operations and financial position.

In October 2004, the American Jobs Creation Act of 2004 (the "Act") was signed into law. Three of the more significant provisions of the Act relate to a one-time opportunity to repatriate foreign earnings at a reduced rate, manufacturing benefits for qualified production activity income and new requirements with respect to deferred compensation plans. The Company has not yet determined the impact, if any, of this Act on its future results of operations or cash flows. Additionally, under new Section 409A of the Internal Revenue Code, created in connection with the Act, the U.S. Treasury Department is directed to issue regulations providing guidance and provide a limited period during which deferred compensation plans may be amended to comply with the requirements of Section 409A. When the regulations are issued, the Company may be required to make modifications to certain compensation plans to comply with Section 409A.

6.     Acquisitions, Divestitures and Ventures

Acquisitions:

On April 6, 2004, the Company acquired CAG (See Notes 1 and 2).

In February 2005, the Company acquired Vinamul, the North American and European emulsion polymer business of Imperial Chemical Industries PLC ("ICI") for $208 million. The Vinamul product line includes vinyl acetate-ethylene copolymers, vinyl acetate homopolymers and copolymers, and acrylic and vinyl acrylic emulsions. Vinamul operates manufacturing facilities in the United States, Canada, the United Kingdom, and The Netherlands. As part of the agreement, ICI will continue to supply Vinamul with starch, dextrin and other specialty ingredients following the acquisition. The Company will supply ICI with vinyl acetate monomer and polyvinyl alcohols. The supply agreements are for 15 years, and the pricing is based on market and other negotiated terms. The Company primarily financed this acquisition through borrowings of $200 million under the amended and restated senior credit facilities (See Note 9). The Company has allocated the purchase price on the basis of its preliminary estimate of the fair value of the assets acquired and the liabilities assumed. The estimated fair value of the total assets, identified intangible assets, and goodwill were approximately $280 million, $16 million, and $40 million, respectively. Pro forma financial information has not been provided as the acquisition did not have a material impact on the Company's results of operations.

In July 2005, the Company acquired Acetex Corporation ("Acetex") for $270 million and assumed Acetex's $235 million of debt, which is net of cash acquired of $66 million. Acetex's operations include an acetyls business with plants in Europe and a North-American specialty polymers and film business. Acetex also previously concluded an agreement for a venture to build an acetyls

18




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

complex in Saudi Arabia and has commenced the technical planning for this facility. The Company acquired Acetex using existing cash. The Company had Acetex exercise its option to redeem its 10 7/8% senior notes due 2009 totaling approximately $265 million. The redemption will be funded primarily with cash on hand and is expected to take place August 19, 2005. The redemption price is expected to be approximately $280 million, which represents 105.438% of the outstanding principal amount, plus accrued and unpaid interest to August 19, 2005.

Divestitures:

In July 2005, in connection with the Vinamul transaction, the Company agreed to sell its emulsion powders business to ICI for approximately $25 million. This transaction includes a proposed supply agreement whereby the Company will supply product to ICI for a period of up to fifteen years. Closing of the transaction is subject to regulatory approval. Net sales for the emulsion powders business for the six months ended June 30, 2005 were approximately $25 million.

In February 2004, the Predecessor sold its acrylates business to The Dow Chemical Company ("Dow") for a sales price of approximately $149 million, which resulted in a pre-tax gain of approximately $14 million in the three months ended March 31, 2004. Dow acquired the Predecessor's acrylates business line, including inventory, intellectual property and technology for crude acrylic acid, glacial acrylic acid, ethyl acrylate, butyl acrylate, methyl acrylate and 2-ethylhexyl acrylate, as well as acrylates production assets at the Clear Lake, Texas facility. In related agreements, the Company provides certain contract manufacturing services to Dow, and Dow supplies acrylates to the Company for use in its emulsions production. Simultaneous with the sale, the Predecessor repaid an unrelated obligation of $95 million to Dow. The acrylates business was part of the Predecessor's Chemical business. As a result of this transaction, the assets, liabilities, revenues and expenses related to the acrylates product lines at the Clear Lake, Texas facility as well as the gain recorded on the sale are reflected as a component of discontinued operations in the consolidated financial statements in accordance with SFAS No. 144.

Discontinued operations of Chemical Products for the three months ended March 31, 2004 had net sales of $21 million and an operating loss of $5 million.

Ventures:

In April 2004, the Company and a group of investors led by Conduit Ventures Ltd. entered into a venture, Pemeas GmbH, which was formed to advance the commercialization of the Company's fuel cell technology. Pemeas GmbH is considered a variable interest entity as defined under FIN No. 46, The Company is deemed the primary beneficiary of this variable interest entity and, accordingly, consolidates this entity in its consolidated financial statements. In December 2004, the Company approved a plan to dispose of the Company's ownership interest in Pemeas GmbH.

7.     Inventories


  As of
June 30, 2005
As of
December 31, 2004
  (in $ millions)
Finished goods   442     470  
Work-in-process   22     26  
Raw materials and supplies   122     122  
Total Inventories   586     618  

As a result of the acquisition of Vinamul (see Note 6), the Company acquired inventory with a fair value of $24 million, which includes $1 million in capitalized manufacturing profit in inventory. The inventory was subsequently sold during the six months ended June 30, 2005.

19




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

8.     Intangible Assets

Goodwill


  Chemical
Products
Acetate
Products
Ticona Performance
Products
Total
  (in $ millions)
Predecessor                              
Carrying value of goodwill as of December 31, 2003   568     161     343         1,072  
Exchange rate changes   (2   (1           (3
Carrying value of goodwill as of March 31, 2004   566     160     343         1,069  
                               
Successor                              
Carrying value of goodwill as of December 31, 2004   193     180     290     84     747  
Acquisition of Vinamul Polymers   40                 40  
Purchase accounting adjustments   8     2     8     2     20  
Exchange rate changes   2     1     3         6  
Carrying value of goodwill as of June 30, 2005   243     183     301     86     813  

In connection with the acquisition of Vinamul (See Note 6), the Company has preliminarily allocated the purchase price to assets acquired and liabilities assumed primarily based on the historical cost of the business acquired. The excess of the purchase price over the amounts allocated to assets and liabilities is included in goodwill, and is preliminarily estimated to be $40 million at June 30, 2005. The Company is in the process of determining the fair value of all assets acquired and liabilities assumed. The Company expects to finalize the purchase accounting for this transaction in 2005.

In the second quarter 2005, the Company increased goodwill $20 million associated with purchase accounting adjustments related to the Acquisition. Included in this adjustment is a $23 million increase to goodwill and the Company's minority interest liability associated with the organizational restructuring that occurred in October 2004 (See Note 2). As this represented an immaterial adjustment, prior periods have not been restated.

In connection with the acquisition of Vinamul Polymers, at the acquisition date, the Company began formulating a plan to exit or restructure certain activities. The Company has not completed this analysis, and as of June 30, 2005, has not recorded any liabilities associated with these activities. As the Company finalizes any plans to exit or restructure activities, it may record additional liabilities, for among other things, severance and severance related costs and such amounts could be material.

Other Intangible Assets


  As of
June 30, 2005
As of
December 31, 2004
  (in $ millions)  
Trademarks and tradenames   68     68  
Customer related intangible assets   365     365  
Developed technology   9     9  
Other intangible assets   10      
Total intangible assets, gross   452     442  
             
Less: accumulated amortization   (63   (42
Total intangible assets, net   389     400  

Aggregate amortization expense charged against earnings for intangible assets with finite lives during the three months ended June 30, 2005 and June 30, 2004 totaled $12 million and $2 million, respectively. Aggregate amortization expense charged against earnings for intangible assets with finite lives during the six months ended June 30, 2005 and the three months ended June 30, 2004 and March 31, 2004 totaled $24 million, $1 million and $2 million, respectively.

20




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

In connection with the acquisition of Vinamul, the Company entered into a five-year non-compete agreement with the seller. The contract has a preliminary fair value of $10 million. In addition, the Company has identified other intangible assets with an estimated value of $6 million. As the Company has not finalized its purchase price allocation, these amounts could change based on final valuations. In addition, other intangible assets may be identified.

9.     Debt


  As of
June 30, 2005
As of
December 31, 2004
  (in $ millions)
Short-term borrowings and current installments of
long-term debt
     
Current installments of long-term debt   49     15  
Short-term borrowings from Affiliates   90     128  
Other   1     1  
Total short-term borrowings and current installments of long-term debt   140     144  
Long-term debt
Senior Credit Facilities:            
Term loan facility   1,725     624  
Floating Rate Term Loan, due 2011       350  
Senior Subordinated Notes 9.625%, due 2014   800     1,231  
Senior Subordinated Notes 10.375%, due 2014   157     272  
Senior Discount Notes 10.5%, due 2014   290     424  
Senior Discount Notes 10%, due 2014   70     103  
Term notes 7.125%, due 2009   14     14  
Pollution control and industrial revenue bonds, interest rates ranging from 5.2% to 6.7%, due at various dates through 2030   191     191  
Obligations under capital leases and other secured borrowings due at various dates through 2018   39     49  
Other borrowings   16      
Subtotal   3,302     3,258  
Less: Current installments of long-term debt   49     15  
Total long-term debt   3,253     3,243  

In the six months ended June 30, 2005, the Company borrowed an additional $1,135 million under the amended and restated senior credit facilities. A portion of these proceeds, coupled with the proceeds from the initial public offering, were used to repay a $350 million floating rate term loan and redeem $188 million of senior discount notes and $521 million of senior subordinated notes, excluding early redemption premiums of $4 million, $19 million and $51 million, respectively. In addition, $200 million was used to finance the February 2005 acquisition of the Vinamul business.

Under the amended and restated facilities, the term loan facility increased to $1,750 million (including €275 million), which matures in 2011. There was also a $242 million delayed draw facility which expired in July 2005.

The revolving credit facility, through a syndication of banks, provides for borrowings of up to $600 million, including the availability of letters of credit in U.S. dollars and euros and for borrowings on same-day notice.

In January 2005, the revolving credit facility was increased from $380 million to $600 million under the amended and restated senior credit facilities. The $228 million credit-linked revolving facility, which matures in 2009, includes borrowing capacity available for letters of credit. As of June 30, 2005, there were $215 million of letters of credit issued under the credit-linked revolving

21




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

facility. As of June 30, 2005, $613 million remained available for borrowing under the revolving credit facilities (taking into account letters of credit issued under the credit-linked revolving credit facility).

The Company is in compliance with all of its covenant agreements as of June 30, 2005.

Interest expense

The components of interest expense are as follows:


  Successor Predecessor
  Three Months
Ended June 30,
2005
Three Months
Ended June 30,
2004
Six Months
Ended June 30,
2005
Three Months
Ended June 30,
2004
Three Months
Ended March 31,
2004
      (in $ millions)    
Accelerated amortization of deferred financing costs on early redemption and prepayment of debt       71     28     71      
Premium paid on early redemption of debt           74          
Other interest expense   68     59     142     59     6  
Total interest expense   68     130     244     130     6  

10.     Benefit Obligations

The components of net periodic benefit costs recognized and contributions made to the pension plans and benefit payments made to other postretirement obligations participants are as follows:


  Defined Benefit Obligations Other Postretirement Obligations
  Successor Successor
  Three Months
Ended June 30,
2005
Three Months
Ended June 30,
2004
Three Months
Ended June 30,
2005
Three Months
Ended June 30,
2004
    (in $ millions)  
Components of net periodic benefit cost for the                        
Service cost   10     10         1  
Interest cost   45     44     6     6  
Expected return on plan assets   (49   (43        
Recognized actuarial loss       1          
Special termination benefit       1          
Net periodic benefit cost   6     13     6     7  

22




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)


  Defined Benefit Obligations Other Postretirement Obligations
  Successor Predecessor Successor Predecessor
  Six Months
Ended
June 30, 2005
Three Months
Ended
June 30, 2004
Three Months
Ended
March 31, 2004
Six Months
Ended
June 30, 2005
Three Months
Ended
June 30, 2004
Three Months
Ended
March 31, 2004
      (in $ millions)    
Components of net periodic benefit cost for the                                    
Service cost   20     10     9     1     1     1  
Interest cost   90     44     40     12     6     6  
Expected return on plan assets   (98   (43   (40            
Amortization of prior service cost           1             (1
Recognized actuarial loss       1     6             2  
Special termination benefit       1                  
Curtailment (gain)/loss               (1        
Net periodic benefit cost   12     13     16     12     7     8  

The Company previously disclosed in its financial statements for the year ended December 31, 2004 that it expected to contribute $7 million to its defined benefit pension plans in 2005. As ofJune 30, 2005, $4 million of contributions have been made. The Company presently anticipates contributing an additional $3 million to fund its defined benefit pension plans in 2005.

The Company previously disclosed in its financial statements for the year ended December 31, 2004 that it expected to make benefit payments of $47 million to its other postretirement benefit plans. As of June 30, 2005, $24 million of benefit payments have been made. The Company presently anticipates contributing an additional $23 million to fund its other postretirement benefit plans in 2005.

Contributions to the defined contribution plans are based on specified percentages of employee contributions and aggregated $7 million, $3 million and $3 million for the six months ended June 30, 2005 and the three months ended June 30, 2004 and March 31, 2004, respectively.

In connection with the acquisition of CAG, the Purchaser agreed to pre-fund $463 million of certain pension obligations. During the nine months ended December 31, 2004, $409 million was pre-funded to the Company's pension plans. The Company contributed the remaining $54 million that the Purchaser agreed to pre-fund, as well as an additional $9 million to the non-qualified pension plan's rabbi trusts during the six months ended June 30, 2005.

23




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

11.     Shareholders' Equity (Deficit)

See table below for share activity:


  Preferred
Stock
Series A
Common Stock
Series B
Common Stock
  (number of shares)
Balance as of December 31, 2004           99,377,884  
Issuance of preferred stock   9,600,000          
Issuance of common stock       51,666,917      
Stock dividend       7,500,000      
Conversion of Series B common stock to Series A common stock       99,377,884     (99,377,884
Balance as of June 30, 2005   9,600,000     158,544,801      

Funding for the Acquisition included equity investments from Blackstone Capital Partners (Cayman) Ltd. 1, Blackstone Capital Partners (Cayman) Ltd. 2, and Blackstone Capital Partners (Cayman) Ltd. 3 (collectively, "Blackstone") and BA Capital Investors Sidecar Fund, L.P. (and together with Blackstone, the "Original Shareholders").

On December 31, 2004, the capital structure of the Company consisted of 650,494 shares of Series B common stock, par value $0.01 per share. In January 2005, the Company amended its certificate of incorporation and increased its authorized common stock to 500,000,000 shares and the Company effected a 152.772947 for 1 stock split for the outstanding shares of the Series B common stock. Accordingly, all Successor share information is effected for such stock split effective December 31, 2004.

As a result of the offering in January 2005, the Company now has $240 million aggregate liquidation preference of outstanding preferred stock. Holders of the preferred stock are entitled to receive, when, as and if, declared by the Company's board of directors, out of funds legally available therefor, cash dividends at the rate of 4.25% per annum of liquidation preference, payable quarterly in arrears, commencing on May 1, 2005. Dividends on the preferred stock are cumulative from the date of initial issuance. Accumulated but unpaid dividends accumulate at an annual rate of 4.25%. The preferred stock is convertible, at the option of the holder, at any time into 1.25 shares of Series A common stock per $25.00 liquidation preference of preferred stock and upon conversion will be recorded in shareholders' equity (deficit). As of June 30, 2005, the Company had $2 million of accumulated but unpaid dividends, which have not been declared.

On March 8, 2005, the Company declared a special cash dividend to holders of the Company's Series B common stock of $804 million, which was paid on April 7, 2005. Upon payment of the $804 million dividend, all of the outstanding shares of Series B common stock converted automatically to shares of Series A common stock.

In addition, on March 9, 2005, the Company issued a 7,500,000 Series A common stock dividend to the Original Shareholders of its Series B common stock.

Other Comprehensive Income (Loss)

Other comprehensive income (loss) totaled $(11) million, $(23) million and $(39) million, for the six months ended June 30, 2005, the three months ended June 30, 2004 and the three months ended March 31, 2004, respectively. These amounts were net of tax expense (benefit) of $2 million, less than $1 million and $2 million, for the six months ended June 30, 2005, the three months ended June 30, 2004 and the three months ended March 31, 2004, respectively.

12.     Commitments and Contingencies

The Company is involved in a number of legal proceedings, lawsuits and claims incidental to the normal conduct of our business, relating to such matters as product liability, antitrust, past waste

24




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

disposal practices and release of chemicals into the environment. While it is impossible at this time to determine with certainty the ultimate outcome of these proceedings, lawsuits and claims, management believes that adequate provisions have been made and that the ultimate outcomes will not have a material adverse effect on our financial position, but may have a material adverse effect on the results of operations or cash flows in any given accounting period.

The following disclosure should be read in conjunction with the Company's Annual Report on Form 10-K for the year ended December 31, 2004.

Plumbing Actions

CNA Holdings, Inc. ("CNA Holdings"), a U.S. subsidiary of Celanese, which included the U.S. business now conducted by the Ticona segment, along with Shell Oil Company ("Shell"), E.I. DuPont de Nemours and Company ("DuPont") and others, has been a defendant in a series of lawsuits, including a number of class actions, alleging that plastics manufactured by these companies that were utilized in the production of plumbing systems for residential property were defective or caused such plumbing systems to fail. Based on, among other things, the findings of outside experts and the successful use of Ticona's acetal copolymer in similar applications, CNA Holdings does not believe Ticona's acetal copolymer was defective or caused the plumbing systems to fail. In many cases CNA Holdings' exposure may be limited by invocation of the statute of limitations since CNA Holdings ceased selling the resin for use in the plumbing systems in site built homes during 1986 and in manufactured homes during 1990.

CNA Holdings has been named a defendant in ten putative class actions, as well as a defendant in other non-class actions filed in ten states, the U.S. Virgin Islands, and Canada. In these actions, the plaintiffs typically have sought recovery for alleged property damages and, in some cases, additional damages under the Texas Deceptive Trade Practices Act or similar type statutes. Damage amounts have not been specified.

In order to reduce litigation expenses and to provide relief to qualifying homeowners, in November 1995, CNA Holdings, DuPont and Shell Oil Company entered into national class action settlements, which have been approved by the courts. The settlements call for the replacement of plumbing systems of claimants who have had qualifying leaks, as well as reimbursements for certain leak damage. Furthermore, the three companies have agreed to fund these replacements and reimbursements up to $950 million. As of June 30, 2005, the funding is $1,073 million due to additional contributions and funding commitments made primarily by other parties. There are additional pending lawsuits in approximately 10 jurisdictions not covered by this settlement; however, these cases do not involve (either individually or in the aggregate) a large number of homes, and management does not expect the obligations arising from these lawsuits to have a material adverse effect on the Company.

In 1995, CNA Holdings and Shell Oil Company settled the claims relating to individuals in Texas owning a total of 110,000 property units, who are represented by a Texas law firm, for an amount that will not exceed $170 million. These claimants are also eligible for a replumb of their homes in accordance with terms similar to those of the national class action settlement. CNA Holdings' and Shell Oil Company's contributions under this settlement were subject to allocation as determined by binding arbitration.

In addition, a lawsuit filed in November 1989 in Delaware Chancery Court, between CNA Holdings and various of its insurance companies relating to all claims incurred and to be incurred for the product liability exposure led to a partial declaratory judgment in CNA Holdings' favor. As a result, settlements have been reached with a majority of CNA Holdings' insurers specifying their responsibility for these claims.

In February 2005, CNA Holdings reached a settlement agreement through mediation with another insurer, pursuant to which the insurer paid CNA Holdings $44 million in exchange for the

25




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

release of certain claims against the policy with the insurer. This amount was recorded as a reduction of goodwill as of December 31, 2004 and was received during the six months ended June 30, 2005.

CNA Holdings has accrued its best estimate of its share of the plumbing actions. At June 30, 2005, the Company has remaining accruals of $71 million for this matter. Management believes that the plumbing actions are adequately provided for in the Company's financial statements and that they will not have a material adverse effect on our financial position. However, if the Company were to incur an additional charge for this matter, such a charge would not be expected to have a material adverse effect on our financial position, but may have a material adverse effect on our results of operations or cash flows in any given accounting period. No assurance can be given that the Company's litigation reserves will be adequate or that these reserves will fully recover claims under the Company's insurance policies.

The Company has reached settlements with CNA Holdings' insurers specifying their responsibility for these claims; as a result, the Company has recorded receivables relating to the anticipated recoveries from certain third party insurance carriers. These receivables are based on the probability of collection, an opinion of external counsel, the settlement agreements with the Company's insurance carriers whose coverage level exceeds the receivables and the status of current discussions with other insurance carriers. As of June 30, 2005, the Company has $31 million of receivables related to a settlement with an insurance carrier. This receivable is discounted and recorded within other assets as it will be collected over the next three years.

Sorbates Antitrust Actions

In May 2002, the European Commission informed Hoechst of its intent to investigate officially the sorbates industry. In early January 2003, the European Commission served Hoechst, Nutrinova, Inc., a U.S. subsidiary of Nutrinova Nutrition Specialties & Food Ingredients GmbH, previously a wholly owned subsidiary of Hoechst, and a number of competitors with a statement of objections alleging unlawful, anticompetitive behavior affecting the European sorbates market. In October 2003, the European Commission ruled that Hoechst, Chisso Corporation, Daicel Chemical Industries Ltd., The Nippon Synthetic Chemical Industry Co. Ltd. and Ueno Fine Chemicals Industry Ltd. operated a cartel in the European sorbates market between 1979 and 1996. The European Commission imposed a total fine of €138 million, of which €99 million was assessed against Hoechst. The case against Nutrinova was closed. The fine against Hoechst is based on the European Commission's finding that Hoechst does not qualify under the leniency policy, is a repeat violator and, together with Daicel, was a co-conspirator. In Hoechst's favor, the European Commission gave a discount for cooperating in the investigation. Hoechst appealed the European Commission's decision in December 2003, and that appeal is still pending.

In addition, several civil antitrust actions by sorbates customers, seeking monetary damages and other relief for alleged conduct involving the sorbates industry, have been filed in U.S. state and federal courts naming Hoechst, Nutrinova, and our other subsidiaries, as well as other sorbates manufacturers, as defendants. Many of these actions have been settled and dismissed by the court. One private action, Kerr v. Eastman Chemical Co. et al. , is still pending in the Superior Court of New Jersey, Law Division, Gloucester County. The plaintiff alleges violations of the New Jersey Antitrust Act and the New Jersey Consumer Fraud Act and seeks unspecified damages.

In July 2001, Hoechst and Nutrinova entered into an agreement with the Attorneys General of 33 states, pursuant to which the statutes of limitations were tolled pending the states' investigations. This agreement expired in July 2003. Since October 2002, the Attorneys General for several states filed suit on behalf of indirect purchasers in their respective states, all of which have been either settled or dismissed, except as noted below. The Nevada action has been dismissed as to Hoechst, Nutrinova and CAG; however, a motion for reconsideration is still pending. The New York action, New York v.

26




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

Daicel Chemical Industries Ltd., et al. is pending in the New York State Supreme Court, New York County, and seeks unspecified damages. All antitrust claims in this matter were dismissed by the court in September 2004; however, other state law claims in New York are still pending. Hoechst and Nutrinova have filed an appeal of the court's denial of the motion to dismiss those remaining claims. In January 2005, Hoechst, Nutrinova, and other subsidiaries, as well as other sorbates manufacturers, entered into a settlement agreement with the Attorneys General of Connecticut, Florida, Hawaii, Maryland, South Carolina, Oregon and Washington. Pursuant to the terms of the settlement agreement, the defendants agreed to refrain from engaging in anticompetitive conduct with respect to the sale or distribution of sorbates and pay approximately $1 million to the states in satisfaction of all released claims.

Based on the advice of external counsel and a review of the existing facts and circumstances relating to the sorbates matter, including the status of government investigations, as well as civil claims filed and settled, the Company has remaining accruals of $130 million. This amount is included in current liabilities at June 30, 2005 for the estimated loss relative to this matter. Although the outcome of this matter cannot be predicted with certainty, management's best estimate of the range of possible additional future losses and fines (in excess of amounts already accrued), including any that may result from the above noted governmental proceedings, as of June 30, 2005 is between $0 and $9 million. The estimated range of such possible future losses is management's best estimate based on the advice of external counsel taking into consideration potential fines and claims, both civil and criminal, that may be imposed or made in other jurisdictions.

Pursuant to the Demerger Agreement with Hoechst, Celanese AG was assigned the obligation related to the sorbates matter. However, Hoechst agreed to indemnify Celanese AG for 80 percent of any costs Celanese may incur relative to this matter. Accordingly, Celanese AG has recognized a receivable from Hoechst and a corresponding contribution of capital, net of tax, from this indemnification. As of June 30, 2005, the Company has receivables, recorded within other current assets, relating to the sorbates indemnification from Hoechst totaling $104 million. Although the outcome of the foregoing proceedings and claims cannot be predicted with certainty, the Company believes that any resulting liabilities, net of amounts recoverable from Hoechst, will not, in the aggregate, have a material adverse effect on our financial position, but may have a material adverse effect on the results of operations or cash flows in any given period.

Acetic Acid Patent Infringement Matters

Celanese International Corporation v. China Petrochemical Development Corporation—Taiwan Kaohsiung District Court .    On February 7, 2001, Celanese International Corporation filed a private criminal action for patent infringement against China Petrochemical Development Corporation, or CPDC, alleging that CPDC infringed Celanese International Corporation's patent covering the manufacture of acetic acid. This criminal action was subsequently converted to a civil action alleging damages against CPDC based on a period of infringement of five years, 1996-2000, and based on CPDC's own data and as reported to the Taiwanese securities and exchange commission. Celanese International Corporation's patent was held valid by the Taiwanese patent office. The amount of damages claimed by Celanese International Corporation has been reassessed at $35 million. This action is still pending.

Shareholder Litigation

During August 2004, nine actions were brought by minority shareholders against CAG in the Frankfurt District Court ( Landgericht ), all of which were consolidated in September 2004. Several minority shareholders joined these proceedings via a third party intervention in support of the plaintiffs. The Purchaser joined the proceedings via a third party intervention in support of CAG.

27




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

Among other things, these actions request the court to set aside shareholder resolutions passed at the extraordinary general meeting held on July 30 and 31, 2004 based on allegations that include the alleged violation of procedural requirements and information rights of the shareholders.

In a related matter, twenty-seven minority shareholders filed lawsuits in May and June of 2005 in the Frankfurt District Court ( Landgericht ) contesting the shareholder resolutions passed at the annual general meeting held May 19-20, 2005, which confirmed the resolutions passed at the July 30-31, 2004 extraordinary general meeting. The Frankfurt District Court (Landgericht) has suspended the proceedings regarding the resolutions passed at the July 30-31, 2004 extraordinary general meeting described above as long as the lawsuits contesting the confirmatory resolutions are pending. In addition, on May 9, 2005 one minority shareholder brought forward an additional action with the Frankfurt District Court (Landgericht) and requested the court rule that the shareholder resolutions passed at the extraordinary general meeting on July 30-31, 2004 were void based on allegations that certain formal requirements necessary in connection with the invitation to the extraordinary general meeting had been violated. This action has not been suspended.

Further, on August 2, 2004, two minority shareholders instituted public register proceedings with each of the Königstein Local Court ( Amtsgericht ) and the Frankfurt District Court ( Landgericht ), both with a view to have the registration of the Domination Agreement in the Commercial Register deleted ( Amtslöschungsverfahren ). These actions are based on an alleged violation of procedural requirements at the extraordinary general meeting, an alleged undercapitalization of the Purchaser and Blackstone and an alleged misuse of discretion by the competent court with respect to the registration of the Domination Agreement in the Commercial Register. In April 2005, the court of appeals rejected the demand by one shareholder for injunctive relief, and in June 2005 the Frankfurt District Court (Landgericht) ruled that it does not have jurisdiction over this matter. The claims in the Königstein Local Court (Amtsgericht) are still pending.

Based upon information available as of June 30, 2005, the outcome of the foregoing proceedings cannot be predicted with certainty. Except for certain challenges on limited grounds, the time period to bring forward challenges has expired.

The amounts of the fair cash compensation ( Abfindung ) and of the guaranteed fixed annual payment ( Ausgleich ) offered under the Domination Agreement may be increased in special award proceedings ( Spruchverfahren ) initiated by minority shareholders, which may further reduce the funds the Purchaser can otherwise make available to the Company. Several minority shareholders of CAG had initiated special award proceedings seeking the court's review of the amounts of the fair cash compensation ( Abfindung ) and of the guaranteed fixed annual payment ( Ausgleich ) offered under the Domination Agreement. As a result of these proceedings, the amount of the fair cash consideration and the guaranteed fixed annual payment offered under the Domination Agreement could be increased by the court so that all minority shareholders, including those who have already tendered their shares into the mandatory offer and have received the fair cash compensation could claim the respective higher amounts. This could reduce the funds the Purchaser can make available to the Company and its subsidiaries and, accordingly, diminish our ability to make payments on our indebtedness. However, the court dismissed all of these proceedings in March 2005 on the grounds of inadmissibility. The dismissal has been appealed.

In February 2005, a minority shareholder also brought a lawsuit against the Purchaser, as well as a former member of CAG's board of management and a former member of CAG's supervisory board, in the Frankfurt District Court (Landgericht) . Among other things, this action seeks to unwind the tender of the plaintiff's shares in the Acquisition and seeks compensation for damages suffered as a consequence of tendering such shares. The court ruled against the plaintiff in this matter in June 2005. The plaintiff appealed this decision with respect to the Purchaser and the former member of the CAG board of management; however, with respect to the former member of the CAG supervisory board, the plaintiff has accepted the court's ruling.

28




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

Based upon the information as available, the outcome of the foregoing proceedings cannot be predicted with certainty.

Guarantees

The Company has agreed to guarantee or indemnify third parties for environmental and other liabilities pursuant to a variety of agreements, including asset and business divestiture agreements, leases, settlement agreements, and various agreements with affiliated companies. Although many of these obligations contain monetary and/or time limitations, others do not provide such limitations.

The Company has accrued for all probable and reasonably estimable losses associated with all known matters or claims that have been brought to its attention.

These known obligations include the following:

Demerger Obligations

The Company has obligations to indemnify Hoechst for various liabilities under the Demerger Agreement as follows:

•  The Company agreed to indemnify Hoechst for environmental liabilities associated with contamination arising under 19 divestiture agreements entered into by Hoechst prior to the demerger.

The Company's obligation to indemnify Hoechst is subject to the following thresholds:

•  The Company will indemnify Hoechst against those liabilities up to €250 million;
•  Hoechst will bear those liabilities exceeding €250 million, however the Company will reimburse Hoechst for one-third of those liabilities for amounts that exceed €750 million in the aggregate.

The Company's obligation regarding two agreements has been settled. The aggregate maximum amount of environmental indemnifications under the remaining divestiture agreements that provide for monetary limits is €750 million. Three of the divested agreements do not provide for monetary limits.

Based on the estimate of the probability of loss under this indemnification, the Company has reserves of $36 million as of June 30, 2005, for this contingency. Where the Company is unable reasonably to determine the probability of loss or estimate such loss under an indemnification, the Company has not recognized any related liabilities.

The Company has also undertaken in the Demerger Agreement to indemnify Hoechst to the extent that Hoechst is required to discharge liabilities, including tax liabilities, associated with businesses that were included in the demerger where such liabilities were not demerged, due to legal restrictions on the transfers of such items. These indemnities do not provide for any monetary or time limitations. The Company has not provided for any reserves associated with this indemnification. Neither the Company nor the Predecessor made any payments to Hoechst in the six months ended June 30, 2005 or 2004, in connection with this indemnification.

Divestiture Obligations

The Company and its predecessor companies agreed to indemnify third party purchasers of former businesses and assets for various pre-closing conditions, as well as for breaches of representations, warranties and covenants. Such liabilities also include environmental liability, product liability, antitrust and other liabilities. These indemnifications and guarantees represent standard contractual terms associated with typical divestiture agreements and, other than environmental liabilities, the Company does not believe that they expose the Company to any significant risk.

29




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

The Company and the Predecessor have divested in the aggregate over 20 businesses, investments and facilities, through agreements containing indemnifications or guarantees to the purchasers. Many of the obligations contain monetary and/or time limitations, ranging from one year to 30 years, the aggregate amount of guarantees provided for under these agreements is approximately $2.9 billion as of June 30, 2005. Other agreements do not provide for any monetary or time limitations.

Based on historical claims experience and its knowledge of the sites and businesses involved, the Company believes that it is adequately reserved for these matters. As of June 30, 2005, the Company has reserves in the aggregate of $46 million for all such environmental matters.

Plumbing Insurance Indemnifications

CAG entered into agreements with insurance companies related to product liability settlements associated with Celcon ® plumbing claims. These agreements, except those with insolvent insurance companies, require the Company to indemnify and/or defend these insurance companies in the event that third parties seek additional monies for matters released in these agreements. The indemnifications in these agreements do not provide for time limitations.

In certain of the agreements, CAG received a fixed settlement amount. The indemnities under these agreements generally are limited to, but in some cases are greater than, the amount received in settlement from the insurance company. The maximum exposure under these indemnifications is $95 million. Other settlement agreements have no stated limits.

There are other agreements whereby the settling insurer agreed to pay a fixed percentage of claims that relate to that insurer's policies. The Company has provided indemnifications to the insurers for amounts paid in excess of the settlement percentage. These indemnifications do not provide for monetary or time limitations.

The Company has reserves associated with these product liability claims. See Plumbing Actions above.

Other Obligations

•  The Company is secondarily liable under a lease agreement pursuant to which the Company has assigned a direct obligation to a third party. The lease assumed by the third party expires on April 30, 2012. The lease liability for the period from July 1, 2005 to April 30, 2012 is estimated to be approximately $52 million.
•  The Company has agreed to indemnify various insurance carriers, for amounts not in excess of the settlements received, from claims made against these carriers subsequent to the settlement. The aggregate amount of guarantees under these settlements is approximately $10 million, which is unlimited in term.

As indemnification obligations often depend on the occurrence of unpredictable future events, the future costs associated with them cannot be determined at this time. However, the Company were to incur additional charges for these matters, such charges may have a material adverse effect on the financial position, results of operations or cash flows of the Company in any given accounting period.

Other Matters

As of June 30, 2005, Celanese Ltd. and/or CNA Holdings, Inc., both our U.S. subsidiaries, are defendants in approximately 680 asbestos cases. Because many of these cases involve numerous plaintiffs, the Company is subject to claims significantly in excess of the number of actual cases. The Company has reserves for defense costs related to claims arising from these matters. The Company believes that there is not significant exposure related to these matters.

30




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

Under the transaction and monitoring fee agreement/sponsor services agreement, the Company has agreed to indemnify the Advisor and its affiliates and their respective partners, members, directors, officers, employees, agents and representatives for any and all losses relating to services contemplated by these agreements and the engagement of the Advisor pursuant to, and the performance by the Advisor or the services contemplated by, these agreements. The Company has also agreed under the transaction and monitoring fee agreement/sponsor services agreement to reimburse the Advisor and its affiliates for their expenses incurred in connection with the services provided under these agreements or in connection with their ownership or subsequent sale of Celanese Corporation stock (See Note 17).

On July 31, 2003, a federal district court ruled that the formula used in International Business Machine Corporation's ("IBM") cash balance pension plan violated the age discrimination provisions of the Employee Retirement Income Security Act of 1974. The IBM decision, however, conflicts with the decisions from two other federal district courts and with the proposed regulations for cash balance plans issued by the Internal Revenue Service in December 2002. IBM has announced that it will appeal the decision to the United States Court of Appeals for the Seventh Circuit. The effect of the IBM decision on the Company's cash balance plan cannot be determined at this time.

13.     Special Charges

The components of special charges were as follows:


  Successor
  Three Months Ended
June 30, 2005
Three Months Ended
June 30, 2004
  (in $ millions)
Employee termination benefits   (7   (1
Total Restructuring   (7   (1
Asset impairments   (24    
Insurance recoveries associated with plumbing cases   4     2  
Total Special Charges   (27   1  

  Successor Predecessor
  Six Months Ended
June 30, 2005
Three Months Ended
June 30, 2004
Three Months Ended
March 31, 2004
    (in $ millions)  
Employee termination benefits   (9   (1   (2
Plant/office closures   (1        
Total Restructuring   (10   (1   (2
Termination of advisor monitoring services   (35        
Asset impairments   (24        
Advisory services           (25
Insurance recoveries associated with plumbing cases   4     2      
Other           (1
Total Special Charges   (65   1     (28

Asset impairments primarily consists of revised estimates related to the Company's decision to divest its Cyclo-olefin Copolymer ("COC") business.

31




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

The components of the restructuring reserves were as follows:


  Employee
Termination
Benefits
Plant/Office
Closures
Total
  (in $ millions)
Predecessor                  
Restructuring reserve at December 31, 2003   28     21     49  
Restructuring additions   2         2  
Cash and noncash uses   (5   (2   (7
Restructuring reserve at March 31, 2004   25     19     44  
 
Successor                  
Restructuring reserve at April 1, 2004   25     19     44  
Purchase accounting adjustments   5         5  
Restructuring additions   1         1  
Cash and noncash uses   (2   (3   (5
Restructuring reserve at June 30, 2004   29     16     45  
Restructuring reserve at December 31, 2004   72     14     86  
Purchase accounting adjustments   1         1  
Restructuring additions   9     1     10  
Cash and noncash uses   (21   (6   (27
Currency translation adjustments   (1       (1
Restructuring reserve at June 30, 2005   60     9     69  

14.     Stock-based and Other Management Compensation Plans

In December 2004, the Company approved a stock incentive plan, which included executive officers, key employees and directors, a deferred compensation plan, which included executive officers and key employees, as well as other management incentive programs.

These stock incentive plans allows for the issuance or delivery of up to 16.25 million shares of the Company's Series A common stock through stock options and a discounted share program. In January 2005, options were initially granted at an exercise price equal to the initial public offering price. The options have a ten-year term with vesting terms pursuant to a schedule, with no vesting to occur later than the 8th anniversary of the date of the grant. Accelerated vesting depends on meeting specified performance targets. Of the 11.7 million stock options granted, 10.7 million are non-compensatory. The remaining 1.0 million options are subject to variable plan accounting. Compensation expense related to these options was not material for the three and six months ended June 30, 2005. No options were forfeited or exercised during the six months ended June 30, 2005.

In December 2004, the Company granted rights to executive officers and key employees to purchase up to 1,797,386 shares of Series A common stock at a discount of $8.80 per share. During the six months ended June 30, 2005, 1,666,917 shares have been purchased. As a result of this discounted share offering, the Company recorded a pre-tax non-cash charge of $14 million, with a corresponding adjustment to additional paid-in capital within shareholders' equity (deficit) in the fourth quarter 2004. Compensation expense associated with the discounted shares was immaterial for the six months ended June 30, 2005.

32




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

The deferred compensation plan has an aggregate maximum amount payable of $192 million. The initial component of the deferred compensation plan, totaling an aggregate of approximately $27 million, vested in 2004 and was paid in the first quarter of 2005.

•     Stock-based compensation

As permitted by SFAS No. 123, Accounting for Stock-Based Compensation ("SFAS No. 123"), the Successor accounts for employee stock-based compensation in accordance with APB Opinion No. 25, Accounting for Stock Issued to Employees ("APB No. 25"), using an intrinsic value approach to measure compensation expense, if any.

For the three months ended March 31, 2004, the Predecessor accounted for stock options and similar equity instruments under the fair value method, which requires compensation cost to be measured at the grant date based on the value of the award.

The fair value of options granted in the six months ended June 30, 2005 under the Company's stock incentive plan was estimated at the date of grant using the Black Scholes option pricing model. The following weighted average assumptions were used:


Risk free interest rate 3.9%
Estimated life in years 6.7
Dividend yield 0.75%
Volatility 26%

The weighted average fair value of options granted was $5.21 per option.

The following table illustrates the effect on net earnings (loss) and related per share amounts if the Successor had applied the fair value recognition provisions of SFAS No. 123 to stock-based employee compensation:


  For the Three Months Ended June 30, 2005 For the Six Months Ended June 30, 2005
  Earnings
(Loss)
Basic
Earnings
Per Common
Share
Diluted
Earnings
Per Common
Share
Earnings
(Loss)
Basic
Earnings
Per Common
Share
Diluted
Earnings
Per Common
Share
  (in $ millions, except per share information)
Net earnings, as reported   67     0.41     0.39     57     0.35     0.35  
Less: stock-based compensation under SFAS No. 123   (4   (0.03   (0.02   (6   (0.04   (0.04
Pro forma net earnings   63     0.38     0.37     51     0.31     0.31  

15.     Income Taxes

Income taxes for the three and six months ended June 30, 2005 and the three months ended June 30, 2004, are recorded based on the estimated annual effective tax rate. As of June 30, 2005, the estimated annualized tax rate for 2005 is 35%, which is slightly less than the combination of the statutory rate and state income tax rates in the U.S. The estimated annual effective tax rate for 2005 reflects earnings in low tax jurisdictions, a valuation allowance for the tax benefit associated with projected U.S. losses (which includes the expenses associated with the early redemption of debt), and tax expense in certain non-U.S. jurisdictions.

33




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

For the three months ended June 30, 2004, a tax expense of $10 million was recorded which resulted in a tax rate of negative 10%. This effective tax rate was primarily affected by the non-recognition of tax benefits associated with acquisition related expenses.

The Predecessor had an effective tax rate of 24% for the three months ended March 31, 2004, compared to the German statutory rate of 40%, which was primarily affected by earnings in low tax jurisdictions.

16.     Business Segments


  Chemical
Products
Ticona Acetate
Products
Performance
Products
Total
Segments
Reconciliation Consolidated
        (in $ millions)      
Successor
For the six months ended June 30, 2005                              
Sales to external customers   2,071     462     379     94     3,006     20     3,026  
Inter-segment revenues   58                 58     (58    
Operating profit   332     44     30     28     434     (116   318  
Earnings (loss) from continuing operations before tax and minority interests   342     73     32     26     473     (327   146  
Depreciation and amortization   73     29     18     6     126     4     130  
Capital expenditures   44     23     14     3     84     2     86  
For the three months ended June 30, 2005                              
Sales to external customers   1,056     223     183     47     1,509     8     1,517  
Inter-segment revenues   29                 29     (29    
Operating profit   155     5     10     15     185     (33   152  
Earnings (loss) from continuing operations before tax and minority interests   149     22     12     14     197     (74   123  
Depreciation and amortization   39     14     9     3     65     2     67  
Capital expenditures   26     9     9     1     45     1     46  

34




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)


  Chemical
Products
Ticona Acetate
Products
Performance
Products
Total
Segments
Reconciliation Consolidated
        (in $ millions)      
For the three months ended June 30, 2004                              
Sales to external customers   780     220     173     45     1,218     11     1,229  
Inter-segment revenues   28                 28     (28    
Operating profit   36     11     10     2     59     (34   25  
Earnings (loss) from continuing operations before tax and minority interests   34     26     14     1     75     (179   (104
Depreciation and amortization   38     15     14     2     69     2     71  
Capital expenditures   17     19     13     1     50         50  
 
Predecessor                                          
For the three months ended March 31, 2004                              
Sales to external customers   789     227     172     44     1,232     11     1,243  
Inter-segment revenues   29                 29     (29    
Operating profit   65     31     9     11     116     (64   52  
Earnings (loss) from continuing operations before tax and minority interests   64     45     9     11     129     (57   72  
Depreciation and amortization   39     16     13     2     70     2     72  
Capital expenditures   15     20     8         43     1     44  

17.     Related Party Transactions

Upon closing of the Acquisition, the Company entered into a transaction and monitoring fee agreement with Blackstone Management Partners (the "Advisor"), an affiliate of the Blackstone Group (the "Sponsor"). Under the agreement, the Advisor agreed to provide monitoring services to the Company for a 12 year period. Also, the Advisor may receive additional compensation for providing investment banking or other advisory services provided to the Company by the Advisor or any of its affiliates in connection with any specific acquisition, divestiture, refinancing, recapitalization, or similar transaction. In connection with the completion of the initial public offering, the parties amended and restated the transaction and monitoring fee agreement to terminate the monitoring services and all obligations to pay future monitoring fees and paid the Advisor $35 million. The Company also paid $10 million to the Advisor for the 2005 monitoring fee. The transaction based agreement remains in effect.

In connection with the acquisition of Vinamul, the Company paid the Advisor a fee of $2 million, which was included in the computation of the purchase price for the acquisition. In connection with the acquisition of Acetex, the Company paid the Advisor an initial fee of $1 million, which is included in Other assets. Additional fees of $3 million in the third quarter 2005 became due and payable to the Advisor upon the successful completion of this acquisition.

35




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

18.     Consolidating Guarantor Financial Information

The following unaudited consolidating financial statement information is presented in the provided form because (i) the Issuers are wholly owned subsidiaries of the Parent Guarantor; (ii) the guarantee is considered to be full and unconditional, that is, if the Issuers fail to make a scheduled payment, the Parent Guarantor is obligated to make the scheduled payment immediately and, if they do not, any holder of notes may immediately bring suit directly against the Parent Guarantor for payment of all amounts due and payable. Separate financial statements and other disclosures concerning the Parent Guarantor are not presented because management does not believe that such information is material to investors.

36




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

UNAUDITED CONSOLIDATING STATEMENT OF OPERATIONS INFORMATION


  Successor
  For the Six Months Ended June 30, 2005
  Parent
Guarantor
Issuer Non-Guarantor Eliminations Consolidated
  (in $ millions)
Net sales           3,026         3,026  
Cost of sales           (2,300       (2,300
Selling, general and administrative expenses   (5       (292       (297
Research and development expenses           (46       (46
Special charges:
Insurance recoveries associated with plumbing cases           4         4  
Restructuring, impairment and other special charges           (69       (69
Foreign exchange gain (loss), net           2         2  
Gain (loss) on disposition of assets           (2       (2
Operating profit   (5       323         318  
                               
Equity in net earnings of affiliates   56     95     27     (151   27  
Interest expense       (45   (199       (244
Interest income   6         18         24  
Other income (expense), net           21         21  
Earnings (loss) from continuing operations before tax and minority interests   57     50     190     (151   146  
                               
Income tax provision       6     (57       (51
                               
Earnings (loss) from continuing operations before minority interests   57     56     133     (151   95  
                               
Minority interests           (38       (38
                               
Earnings (loss) from continuing operations   57     56     95     (151   57  
                               
Earnings (loss) from discontinued operations                    
                               
Net earnings (loss)   57     56     95     (151   57  

37




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

UNAUDITED CONSOLIDATING STATEMENT OF OPERATIONS INFORMATION


  Successor
  For the Three Months Ended June 30, 2005
  Parent
Guarantor
Issuer Non-Guarantors Eliminations Consolidated
  (in $ millions)
Net sales           1,517         1,517  
Cost of sales           (1,175       (1,175
Selling, general and administrative expenses   (2       (134       (136
Research and development expenses           (23       (23
Special charges:
Insurance recoveries associated with plumbing cases           4         4  
Restructuring, impairment and other special charges           (31       (31
Foreign exchange gain (loss), net           (1       (1
Gain (loss) on disposition of assets           (3       (3
Operating profit   (2       154         152  
                               
Equity in net earnings of affiliates   68     80     12     (148   12  
Interest expense       (9   (59       (68
Interest income   1         8         9  
Other income (expense), net           18         18  
Earnings (loss) from continuing operations before tax and minority interests   67     71     133     (148   123  
                               
Income tax provision       (3   (40       (43
                               
Earnings (loss) from continuing operations before minority interests   67     68     93     (148   80  
                               
Minority interests           (13       (13
                               
Earning (loss) from continuing operations   67     68     80     (148   67  
Earnings (loss) from discontinued operations                    
Net earnings (loss)   67     68     80     (148   67  

38




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

UNAUDITED CONSOLIDATING STATEMENT OF OPERATIONS INFORMATION


  Successor
  For the Three Months Ended June 30, 2004
  Parent
Guarantor
Issuer Non-Guarantor Eliminations Consolidated
  (in $ millions)
Net sales           1,229         1,229  
Cost of sales           (1,058       (1,058
Selling, general and administrative expenses           (125       (125
Research and development expenses           (22       (22
Special charges:
Insurance recoveries associated with plumbing cases           2         2  
Restructuring, impairment and other special charges           (1       (1
Operating profit           25         25  
                               
Equity in net earnings of affiliates   (116       18     116     18  
Interest expense   (6       (124       (130
Interest income           7         7  
Other income (expense), net   (3       (21       (24
Earnings (loss) from continuing operations before tax and minority interests   (125       (95   116     (104
                               
Income tax provision           (10       (10
                               
Earnings (loss) from continuing operations before minority interests   (125       (105   116     (114
                               
Minority interests           (10       (10
Earnings (loss) from continuing operations   (125       (115   116     (124
Earnings (loss) from discontinued operations           (1       (1
Net earnings (loss)   (125       (116   116     (125

39




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

UNAUDITED CONSOLIDATING STATEMENT OF OPERATIONS INFORMATION


  Predecessor
  For the Three Months Ended, March 31, 2004
  Parent
Guarantor
Issuer Non-Guarantor Eliminations Consolidated
  (in $ millions)
Net sales           1,243         1,243  
Cost of sales           (1,002       (1,002
Selling, general and administrative expenses           (137       (137
Research and development expenses           (23       (23
Special charges:
Restructuring, impairment and other special charges           (28       (28
Gain (loss) on disposition of assets     —         —       (1     —       (1
Operating profit           52         52  
                               
Equity in net earnings of affiliates           12         12  
Interest expense           (6       (6
Interest income           5         5  
Other income (expense), net           9         9  
Earnings (loss) from continuing operations before tax and minority interests           72         72  
                               
Income tax provision           (17       (17
                               
Earnings (loss) from continuing operations before minority interests           55         55  
                               
Minority interests                    
                               
Earnings (loss) from continuing operations           55         55  
                               
Earnings (loss) from discontinued operations           23         23  
                               
Net earnings (loss)           78         78  

40




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

UNAUDITED CONSOLIDATING BALANCE SHEET INFORMATION


  Successor
  As of June 30, 2005
  Parent
Guarantor
Issuer Non-
Guarantors
Eliminations Consolidated
  (in $ millions)
ASSETS                              
Current assets:                              
Cash and cash equivalents   1         958         959  
Receivables, net:                              
Trade receivables, net — third party and affiliates           955         955  
Other receivables   1         524     (2   523  
Inventories           586         586  
Deferred income taxes           75         75  
Other assets           106         106  
Assets of discontinued operations           3         3  
Total current assets   2         3,207     (2   3,207  
Investments   128     474     543     (602   543  
Property, plant and equipment, net           1,756         1,756  
Deferred income taxes       6     30         36  
Other assets       8     644         652  
Goodwill           813         813  
Intangible assets, net           389         389  
Total assets   130     488     7,382     (604   7,396  
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)                              
Current liabilities:                              
Short-term borrowings and current installments of long-term debt — third party and affiliates           140         140  
Accounts payable and accrued liabilities:                              
Trade payables — third party and affiliates   2         680         682  
Other current liabilities   2         739     (2   739  
Deferred income taxes           14         14  
Income taxes payable           230         230  
Liabilities of discontinued operations           7         7  
Total current liabilities   4         1,810     (2   1,812  
Long-term debt       360     2,893         3,253  
Deferred income taxes           227         227  
Benefit obligations           1,003         1,003  
Other liabilities           452         452  
Minority interests           523         523  
Commitments and contingencies                              
Shareholders' equity (deficit)   126     128     474     (602   126  
Total liabilities and shareholders' equity (deficit)   130     488     7,382     (604   7,396  

41




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

UNAUDITED CONSOLIDATING BALANCE SHEET INFORMATION


  Successor
  As of December 31, 2004
  Parent
Guarantor
Issuer Non-
Guarantors
Eliminations Consolidated
  (in $ millions)
ASSETS                              
Current assets:                              
Cash and cash equivalents           838         838  
Receivables, net:                              
Trade receivables, net — third party and affiliates           866         866  
Other receivables           678     (8   670  
Inventories           618         618  
Deferred income taxes           71         71  
Other assets           86         86  
Assets of discontinued operations           2         2  
Total current assets           3,159     (8   3,151  
Investments       406     600     (406   600  
Property, plant and equipment, net           1,702         1,702  
Deferred income taxes           54         54  
Other assets   7     12     739     (2   756  
Goodwill           747         747  
Intangible assets, net           400         400  
Total assets   7     418     7,401     (416   7,410  
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)                        
Current liabilities:                              
Short-term borrowings and current installments of long-term debt — third party and affiliates   1         144     (1   144  
Accounts payable and accrued liabilities:                              
Trade payables — third party and affiliates           722         722  
Other current liabilities   7         888     (7   888  
Deferred income taxes           20         20  
Income taxes payable           214         214  
Liabilities of discontinued operations           7         7  
Total current liabilities   8         1,995     (8   1,995  
Long-term debt       527     2,716         3,243  
Deferred income taxes           256         256  
Benefit obligations           1,000         1,000  
Other liabilities   2         510     (2   510  
Share of subsidiary losses   109             (109    
Minority interests           518         518  
Commitments and contingencies                              
Shareholders' equity (deficit)   (112   (109   406     (297   (112
Total liabilities and shareholders' equity (deficit)   7     418     7,401     (416   7,410  

42




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS INFORMATION


  Successor
  For the Six Months Ended June 30, 2005
  Parent
Guarantor
Issuer Non-
Guarantors
Eliminations Consolidated
  (in $ millions)
Net cash provided by (used in) operating activities   9         181         190  
Investing activities from continuing operations:                              
Capital expenditures on property, plant and equipment           (86       (86
Investments in Subsidiaries, net   (198   9         189      
Acquisition of CAG shares           (6       (6
Fees associated with the acquisitions           (10       (10
Acquisition of Vinamul           (208       (208
Proceeds from sale of assets           14         14  
Net proceeds from disposal of discontinued operations           75         75  
Proceeds from sale of marketable securities           141         141  
Purchases of marketable securities           (59       (59
Other, net           1         —     1  
Net cash provided by (used in) investing activities   (198   9     (138   189     (138
Financing activities from continuing operations:                              
Proceeds from issuance of common stock, net   752                 752  
Proceeds from issuance of preferred stock, net   233                 233  
Proceeds from issuance of discounted common stock   12                 12  
Contribution from parent       779     572     (1,351    
Redemption of senior discount notes, including related premium       (207           (207
Redemption of senior subordinated notes, including related premium           (572       (572
Borrowings under term loan facility           1,135         1,135  
Fees associated with financings           (7       (7
Repayment of floating rate term loan, including related premium           (354       (354
Short-term borrowing (repayments), net           (26       (26
Proceeds (payments) from other long-term debt, net           9         9  
Dividend payments   (3               (3
Distribution to shareholders/parent   (804   (581   (581   1,162     (804
Net cash provided by (used in) financing activities   190     (9   176     (189   168  
Exchange rate effects on cash           (99       (99
Net increase in cash and cash equivalents   1         120         121  
Cash and cash equivalents at beginning of period           838         838  
Cash and cash equivalents at end of period   1         958         959  
Net cash provided by (used in) discontinued operations:                        
Operating activities           (75       (75
Investing activities           75         75  
Net cash provided by (used in) discontinued operations                    

43




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

UNAUDITED CONSOLIDATED STATEMENT OF CASH FLOWS INFORMATION


  Successor
  For the Three Months Ended June 30, 2004
  Parent
Guarantor
Issuer Non-
Guarantors
Eliminations Consolidated
  (in $ millions)
Net cash provided by (used in) operating activities   (3       (104       (107
Investing activities from continuing operations:                              
Capital expenditures on property, plant and equipment           (50       (50
Acquisition of CAG, net of cash acquired           (1,531       (1531
Fees associated with acquisitions           (67       (67
Proceeds on sale of assets           1         1  
Proceeds from sale of marketable securities           27         27  
Purchases of marketable securities           (28       (28
Other, net           (1       —     (1
Net cash provided by (used in) investing activities           (1,649       (1,649
Financing activities from continuing operations:                                            
Initial capitalization           641       641  
Issuance of mandatorily redeemable preferred stock           200       200  
Borrowings under bridge loans           1,565         1,565  
Repayments under bridge loans           (1,565       (1,565
Proceeds from issuance of senior subordinated notes           1,244         1,244  
Proceeds from floating rate term loan           350         350  
Borrowings under term loan facility           389         389  
Short term borrowings (repayments), net           7         7  
Proceeds (payments) from other long term debt, net           (177       (177
Issuance of preferred stock by consolidated subsidiary           15         15  
Fees associated with financings   (18       (152       (170
Distribution from subsidiary   21         (21        
Dividend payments           (1       (1
Net cash provided by (used in) financing activities   3         2,495         2,498  
Exchange rate effects on cash           (26       (26
Net increase in cash and cash equivalents           716         716  
Cash and cash equivalents at beginning of period                    
Cash and cash equivalents at end of period           716         716  
Net cash provided by (used in) discontinued operations:                        
Operating activities                    
Investing activities                    
Net cash provided by (used in) discontinued operations                    
* Amounts included in Non-Guarantors column represent proceeds received directly by the Non-Guarantors, on behalf of the Parent Guarantor. The legal issuer of the mandatorily redeemable preferred stock is the Parent Guarantor.

44




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

UNAUDITED CONSOLIDATING STATEMENT OF CASH FLOWS INFORMATION


  Predecessor
  For the Three Months Ended March 31, 2004
  Parent Issuer Non-
Guarantors
Eliminations Consolidated
  (in $ millions)
Net cash provided by (used in) operating activities           (107       (107
Investing activities from continuing operations:                              
Capital expenditures on property, plant and equipment           (44       (44
Net proceeds from disposal of discontinued operations           139         139  
Proceeds from sale of marketable securities           42         42  
Purchases of marketable securities           (42       (42
Other, net           1         1  
Net cash provided by investing activities           96         96  
Financing activities from continuing operations:                              
Short-term borrowings (repayments), net           (16       (16
Proceeds (payments) of other long-term debt, net           (27       (27
Net cash provided by (used in) financing activities           (43       (43
Exchange rate effects on cash           (1       (1
Net decrease in cash and cash equivalents           (55       (55
Cash and cash equivalents at beginning of period           148         148  
Cash and cash equivalents at end of period           93         93  
Net cash provided by (used in) discontinued operations:                                                   
Operating activities           (139       (139
Investing activities           139         139  
Net cash provided by (used in) discontinued operations                    

45




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)

19.     Earnings (Loss) Per Share


  Three Months Ended June 30, 2005 Three Months Ended June 30, 2004
  Continuing
Operations
Discontinued
Operations
Net earnings
(loss)
Continuing
Operations
Discontinued
Operations
Net earnings
(loss)
  (in $ millions, except for share and per share data)
Earnings (loss)   67             —     67     (124   (1   (125
Less: cumulative undeclared and declared preferred stock dividends   (2       (2            
Earnings (loss) available to common stockholders   65         65     (124   (1   (125
Basic earnings (loss) per common share   0.41         0.41     (1.25   (0.01   (1.26
Diluted earnings (loss) per common share   0.39         0.39     (1.25   (0.01   (1.26
Weighted-average shares — basic   158,530,397         158,530,397     99,377,884     99,377,884     99,377,884  
Assumed conversion of preferred stock   12,000,000         12,000,000              
Weighted-average shares — diluted   170,530,397         170,530,397     99,377,884     99,377,884     99,377,884  

46




CELANESE CORPORATION AND SUBSIDIARIES
NOTES TO THE UNAUDITED INTERIM CONSOLIDATED
FINANCIAL STATEMENTS (Continued)


  Successor Predecessor
  Six Months Ended June 30, 2005 Three Months Ended March 31, 2004
  Continuing
Operations
Discontinued
Operations
Net earnings
(loss)
Continuing
Operations
Discontinued
Operations
Net earnings
(loss)
  (in $ millions, except for share and per share data)
Net earnings (loss)   57         57     55     23     78  
Less: cumulative undeclared and declared preferred stock dividends   (4       (4            
Earnings (loss) available to common shareholders   53         53     55     23     78  
Basic earnings (loss) per common share   0.35         0.35     1.12     0.46     1.58  
Diluted earnings (loss) per common share   0.35         0.35     1.11     0.46     1.57  
Weighted-average shares — basic   150,182,788         150,182,788     49,321,468     49,321,468     49,321,468  
Dilutive stock options   91,140         91,165     390,953     390,953     390,953  
Assumed conversion of preferred stock   12,000,000         12,000,000              
Weighted-average shares — diluted   162,273,928         162,273,953     49,712,421     49,712,421     49,712,421  

Basic earnings (loss) per common share is based on the net earnings available to common shareholders divided by the weighted average number of common shares outstanding during the period. Diluted earnings per common share is based on the net earnings available to common shareholders divided by the weighted average number of common shares outstanding during the period adjusted to give effect to common stock equivalents, if dilutive.

For the three months ended June 30, 2005, the Company had 11.7 million employee stock options outstanding. which were excluded from the calculation of dilutive earnings (loss) per common share as their impact would be anti-dilutive.

Prior to the completion of the initial public offering of Celanese Corporation Series A common stock in January 2005, the Company effected a 152.772947 for 1 stock split of outstanding shares of common stock (see Note 11). Accordingly, basic and diluted shares for the three months ended March 31, 2005 have been calculated based on the weighted average shares outstanding, adjusted for the stock split. Earnings per common share for the Predecessor periods has been calculated by dividing net earnings available to common shareholders by the historical weighted average shares outstanding of the Predecessor. As the capital structure of the Predecessor and Successor are different, the reported earnings (loss) per common share are not comparable.

47




Item 2.    Management's Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of the financial condition and the results of operations of Celanese Corporation and its subsidiaries (collectively, the "Company" or the "Successor") together with the Unaudited Interim Consolidated Financial Statements and the notes to those financial statements, which were prepared in accordance with U.S. GAAP and with the Celanese Corporation and its subsidiaries consolidated financial statements for the nine months ended December 31, 2004, as filed with the Securities Exchange Commission on Form 10-K.

The following discussion and analysis of financial condition and results of operations cover periods prior and subsequent to the acquisition of Celanese AG and its subsidiaries (collectively "CAG" or the "Predecessor"). Accordingly, the discussion and analysis of historical periods prior to the acquisition do not reflect the significant impact that the acquisition of CAG has had and will have on the Successor, including increased leverage and liquidity requirements as well as purchase accounting adjustments. In addition, investors are cautioned that the forward-looking statements contained in this section involve both risk and uncertainty. Several important factors could cause actual results to differ materially from those anticipated by these statements. Many of these statements are macroeconomic in nature and are, therefore, beyond the control of management. See "Forward-Looking Information" located at the end of this section.

Reconciliation of Non-U.S. GAAP Measures: Management believes that using non-U.S. GAAP financial measures to supplement U.S. GAAP results is useful to investors because such use provides a more complete understanding of the factors and trends affecting the business other than disclosing U.S. GAAP results alone. In this regard, we disclose net debt, which is a non-U.S. GAAP financial measure. Net debt is defined as total debt less cash and cash equivalents. Management uses net debt to evaluate the Company's capital structure. Net debt is not a substitute for any U.S. GAAP financial measure. In addition, the calculation of net debt contained in this report may not be consistent with that of other companies. The most directly comparable financial measure presented in accordance with U.S. GAAP in our financial statements for net debt is total debt. For a reconciliation of net debt and total debt, see "Financial Highlights" below.

Basis of Presentation

Impact of the Acquisition of Celanese AG

On April 6, 2004, Celanese Europe Holding GmbH & Co. KG (the "Purchaser"), an indirect wholly owned subsidiary of the Successor, acquired approximately 84% of the Celanese AG ordinary shares, excluding treasury shares ("CAG Shares"). The ordinary shares were acquired at a price of €32.50 per share or an aggregate purchase price of $1,693 million, including direct acquisition costs of approximately $69 million. During the nine months ended December 31, 2004 and the six months ended June 30, 2005, the Purchaser acquired additional CAG Shares for a purchase price of $33 million and $6 million, respectively. As the additional shares acquired primarily represented exercised employee stock options, the Purchaser's ownership percentage remained at approximately 84% as of December 31, 2004 and June 30, 2005. The additional CAG Shares were acquired pursuant to a mandatory offer commenced in September 2004 that will expire in October 1, 2005, unless further extended.

We accounted for the acquisition of CAG using the purchase method of accounting and, accordingly, this resulted in a new basis of accounting. The purchase price was allocated based on the fair value of the underlying assets acquired and liabilities assumed. The assets acquired and liabilities assumed are reflected at fair value for the approximately 84% portion acquired and at CAG historical basis for the remaining approximate 16%. The excess of the total purchase price over the fair value of the net assets acquired at closing was allocated to goodwill, and this indefinite lived asset is subject to an annual impairment review. During the three months ended March 31, 2005, the Company finalized its purchase accounting adjustments for the acquisition of CAG. (See Notes 2 and 8 to the Unaudited Interim Consolidated Financial Statements).

48




Impact of the Acquisition of Vinamul

In February 2005, the Company acquired Vinamul, the North American and European emulsion polymer business of Imperial Chemical Industries PLC ("ICI") for $208 million. The Vinamul product line includes vinyl acetate-ethylene copolymers, vinyl acetate homopolymers and copolymers, and acrylic and vinyl acrylic emulsions. Vinamul operates manufacturing facilities in the United States, Canada, the United Kingdom, and The Netherlands. As part of the agreement, ICI will continue to supply Vinamul with starch, dextrin and other specialty ingredients following the acquisition. The Company will supply ICI with vinyl acetate monomer and polyvinyl alcohols. The supply agreements are for 15 years, and the pricing is based on market and other negotiated terms. The Company primarily financed this acquisition through borrowings of $200 million under the amended and restated senior credit facilities (See Notes 6 and 9 to the Unaudited Interim Consolidated Financial Statements).

In connection with the acquisition of Vinamul, the Company has preliminarily allocated the purchase price to assets acquired and liabilities assumed primarily based on the historical cost of the business acquired. The excess of the purchase price over the amounts allocated to assets and liabilities is included in goodwill, and is preliminarily estimated to be $40 million at June 30, 2005. The Company is in the process of determining the fair value of all assets acquired and liabilities assumed. The Company expects to finalize the purchase accounting for this transaction in 2005.

In connection with the acquisition of Vinamul, at the acquisition date, the Company began formulating a plan to exit or restructure certain activities. The Company has not completed this analysis, and as of June 30, 2005, has not recorded any liabilities associated with these activities. As the Company finalizes any plans to exit or restructure activities, it may record additional liabilities, for among other things, severance and severance related costs and such amounts could be material.

Successor

Successor—Represents the Company's unaudited consolidated financial position as of June 30, 2005 and December 31, 2004 and its unaudited consolidated results of operations for the three months ended June 30, 2005, March 31, 2005 and June 30, 2004 and for the six months ended June 30, 2005 and cash flows for the six months ended June 30, 2005 and for the three months ended June 30, 2004. These consolidated financial statements reflect the application of purchase accounting, described above, relating to the acquisition of CAG and preliminary purchase price accounting adjustments relating to the acquisition of Vinamul.

Predecessor

Predecessor—Represents CAG's consolidated results of operations and cash flows for the three months ended March 31, 2004. These consolidated financial statements relate to periods prior to the acquisition of CAG and Vinamul and present CAG's historical basis of accounting without the application of purchase accounting.

The results of the Successor are not comparable to the results of the Predecessor due to the difference in the basis of presentation of purchase accounting as compared to historical cost.

Initial Public Offering and Concurrent Financings

In January 2005, the Company completed an initial public offering of 50,000,000 shares of Series A common stock and received net proceeds of $752 million after deducting underwriters' discounts and offering expenses of $48 million. Concurrently, the Company received net proceeds of $233 million from the offering of 9,600,000 shares of convertible perpetual preferred stock after deducting underwriters' discounts and offering expenses of $7 million. A portion of the proceeds of the share offerings were used to redeem $188 million of senior discount notes and $521 million of senior subordinated notes, excluding early redemption premiums of $19 million and $51 million, respectively.

Subsequent to the closing of the initial public offering, the Company borrowed an additional $1,135 million under the amended and restated senior credit facilities, a portion of which was used to

49




repay a $350 million floating rate term loan, which excludes a $4 million early redemption premium, and $200 million of which was used as the primary financing for the February 2005 acquisition of the Vinamul emulsions business. Additionally, the amended and restated senior credit facilities include a $242 million delayed draw term loan. The delayed draw term loan expired unutilized in July 2005.

On April 7, 2005, the Company used the remaining proceeds of the initial public offering and concurrent financings to pay a special cash dividend to holders of the Company's Series B common stock of $804 million, which was declared on March 8, 2005. In addition, on March 9, 2005, the Company issued a 7,500,000 Series A common stock dividend to the holders of its Series B common stock which was declared on March 8, 2005. After payment of the $804 million dividend, all of the outstanding shares of Series B common stock converted automatically into shares of Series A common stock.

Recent Business Highlights:

•  Completed the acquisition of Acetex Corporation in July 2005 to strengthen the Company's positioning in acetyls chemicals. Acetex debt is expected to be retired primarily with cash on hand in August 2005.
•  Began purchasing methanol from Southern Chemical Corporation in an arrangement that is expected to yield significant savings.
•  Realized savings from restructuring and productivity improvements in the three months ended June 30, 2005 in all business segments Discontinued production of certain acetate flake and filament operations, relocated the Acetate Products headquarters to Dallas. Announced closure and relocation of the Bedminster, N.J., financial functions to Dallas by mid-2006.
•  Announced intention to build a state-of-the-art vinyl acetate ethylene and conventional emulsion polymer facility in China. Startup is targeted for the first half of 2007.
•  Announced plans to construct a world-scale plant for the manufacture of GUR® ultra high molecular weight polyethylene in Asia. Production is expected to begin in the second half of 2007.
•  Continued to focus the product portfolio by exiting non-strategic businesses, such as the high performance polymer polybenzamidazole ("PBI"), Vectran polymer, and emulsion powders.
•  Adopted a policy to pay common shareholders dividend of $0.16 per share annually, or 1%, based on the initial public offering price of $16 per share. The first quarterly dividend of $0.04 per share was paid on August 11, 2005.

Overview

Three Months Ended June 30, 2005 Compared with Three Months Ended June 30, 2004

In the three months ended June 30, 2005, net sales rose 23% to $1,517 million compared to $1,229 million in the same period last year primarily on higher pricing, mainly in Chemical Products, and the sales of the recently acquired Vinamul emulsions business, which closed in the first quarter of 2005. Operating profit rose significantly to $152 million versus $25 million last year on margin expansion principally driven by higher pricing and productivity improvements. These effects more than offset higher raw material and energy costs, mainly for ethylene and natural gas, and higher special charges. Operating profit in 2004 included a $49 million charge for a non-cash inventory-related purchase accounting adjustment. The Company recorded net earnings of $67 million compared to a net loss of $125 million, which included $71 million of deferred financing costs for the prepayment of the senior subordinated bridge loan facilities. The second quarter of 2005 benefited from higher operating profit and a $40 million favorable change in our net foreign currency gain (loss) resulting from exchange rate movements and a change from a net asset to a net liability foreign currency position.

Three Months Ended March 31, 2005 Compared with Three Months Ended March 31, 2004

In the three months ended March 31, 2005, net sales rose 21% to $1,509 million compared to $1,243 million, in the same period last year, primarily on significant higher pricing. Higher volumes,

50




favorable currency movements and composition changes, of which $66 million was related to the Vinamul emulsions acquisition, increased net sales. The Company recorded a net loss of $10 million compared to earnings of $78 million for CAG largely due to higher interest expense, which included $102 million in refinancing related costs (comprising early redemption premiums and accelerated amortization of deferred financing costs of $74 million and $28 million, respectively), and higher special charges, mainly due to $35 million in expenses for the termination of sponsor monitoring services. The three months ended March 31, 2005 benefited from higher pricing mainly in Chemical Products, driven by strong demand and higher industry capacity utilization. The Company also benefited from cost savings resulting from restructuring and productivity improvement programs as well as lower depreciation and amortization. These benefits were partially offset by higher raw materials and energy costs.

    Financial Highlights


  Successor Successor Successor Predecessor
  Three Months
Ended June
30, 2005
Three Months
Ended June
30, 2004
Six Months
Ended June
30, 2005
Three Months
Ended March
31, 2004
  (in $ millions)
Statement of Operations Data:
Net sales   1,517     1,229     3,026     1,243  
Special charges   (27   1     (65   (28
Operating profit   152     25     318     52  
Earnings (loss) from continuing operations before tax and minority interests   123     (104   146     72  
Earnings (loss) from continuing operations   67     (124   57     55  
Earnings (loss) from discontinued operations       (1       23  
Net earnings (loss)   67     (125   57     78  

  Successor
  As of June 30,
2005
As of
December 31,
2004
  (in $ millions)  
Balance Sheet Data:
Short-term borrowings and current installments of long-term debt - third party and affiliates   140     144  
Plus: Long-term debt   3,253     3,243  
Total debt   3,393     3,387  
Less: Cash and cash equivalents   959     838  
Net debt   2,434     2,549  

  Successor Successor Successor Predecessor
  Three Months
Ended June
30, 2005
Three Months
Ended June
30, 2004
Six Months
Ended June
30, 2005
Three Months
Ended March
31, 2004
  (in $ millions)  
Other Data:
Depreciation and amortization   67     71     130     72  
Operating margin (1)   10.0   2.0   10.5   4.2
Earnings (loss) from continuing operations before tax and minority interests as a percentage of net sales   8.1   (8.5 )%    4.8   5.8
(1) Defined as operating profit divided by net sales.

51




Selected Data by Business Segment –Three Months Ended June 30, 2005 Compared with Three Months Ended June 30, 2004


  Successor Successor  
  Three
Months
Ended
June 30,
2005
Three
Months
Ended
June 30,
2004
Change in
$
  (in $ millions)  
Net Sales                  
Chemical Products   1,085     808     277  
Technical Polymers Ticona   223     220     3  
Acetate Products   183     173     10  
Performance Products   47     45     2  
Segment Total   1,538     1,246     292  
Other Activities   8     11     (3
Intersegment Eliminations   (29   (28   (1
Total Net Sales   1,517     1,229     288  
                   
Special Charges                  
Chemical Products   (3   (1   (2
Technical Polymers Ticona   (20   2     (22
Acetate Products            
Performance Products            
Segment Total   (23   1     (24
Other Activities   (4       (4
Total Special Charges   (27   1     (28
                   
Operating Profit (Loss)                  
Chemical Products   155     36     119  
Technical Polymers Ticona   5     11     (6
Acetate Products   10     10      
Performance Products   15     2     13  
Segment Total   185     59     126  
Other Activities   (33   (34   1  
Total Operating Profit   152     25     127  
                   
Earnings (Loss) from Continuing Operations
Before Tax and Minority Interests
                 
Chemical Products   149     34     115  
Technical Polymers Ticona   22     26     (4
Acetate Products   12     14     (2
Performance Products   14     1     13  
Segment Total   197     75     122  
Other Activities   (74   (179   105  
Total Earnings (Loss) from Continuing Operations
Before Tax and Minority Interests
  123     (104   227  

52




Selected Data by Business Segment –Three Months Ended June 30, 2005 Compared with Three Months Ended June 30, 2004 (Continued)


  Successor Successor  
  Three
Months
Ended
June 30,
2005
Three
Months
Ended
June 30,
2004
Change in
$
  (in $ millions)  
Depreciation & Amortization                  
Chemical Products   39     38     1  
Technical Polymers Ticona   14     15     (1
Acetate Products   9     14     (5
Performance Products   3     2     1  
Segment Total   65     69     (4
Other Activities   2     2      
Total Depreciation & Amortization   67     71     (4

Factors Affecting Second Quarter 2005 Segment Sales Compared to Second Quarter 2004


in percent Volume Price Currency Other* Total
Chemical Products   (1 )%    21   2   12   34
Technical Polymers Ticona   (5   4     2         1  
Acetate Products   1     5             6  
Performance Products   2     (3   5         4  
Segment Total   (2 )%    15   2   8   23
* Primarily represents sales of the recently acquired Vinamul emulsion business

53




Summary by Business Segment—Three Months Ended June 30, 2005 Compared with Three Months Ended June 30, 2004

        Chemical Products


  Successor Successor  
in $ millions (except for percentages) Three Months
Ended June 30,
2005
Three Months
Ended June 30,
2004
Change in
$
Net sales   1,085     808     277  
Net sales variance:                  
     Volume   (1 )%             
     Price   21            
     Currency   2            
     Other   12            
Operating profit   155     36     119  
Operating margin   14.3   4.5      
Special charges   (3   (1   (2
Earnings (loss) from continuing operations before tax and
minority interests
  149     34     115  
Depreciation and amortization   39     38     1  

    Three Months Ended June 30, 2005 Compared with Three Months Ended June 30, 2004

Chemical Products' net sales increased 34% to $1,085 million compared to the same period last year on significantly higher pricing, sales of the newly acquired Vinamul business and favorable currency movements. Major business lines continued to operate at high utilization rates while volumes declined for non-core derivative products. Pricing increased for most chemical products, particularly vinyl acetate, acetic acid and acetate esters, driven by continued strong demand, high utilization rates across the industry and higher raw material costs, mainly for ethylene and natural gas.

Earnings from continuing operations before tax and minority interests increased to $149 million from $34 million on higher pricing and productivity improvements, which were partly offset by higher raw material costs. Earnings in 2004 included a $15 million charge for a non-cash inventory-related purchase accounting adjustment.

54




        Technical Polymers Ticona


  Successor Successor  
in $ millions (except for percentages) Three Months
Ended June 30,
2005
Three Months
Ended June 30,
2004
Change in
$
Net sales   223     220     3  
Net sales variance:                  
    Volume   (5 )%             
     Price   4
    Currency   2            
Operating profit   5     11     (6
Operating margin   2.2   5.0      
Special charges   (20   2     (22
Earnings (loss) from continuing operations before tax
and minority interests
  22     26     (4
Depreciation and amortization   14     15     (1

    Three Months Ended June 30, 2005 Compared with Three Months Ended June 30, 2004

Ticona's net sales increased 1% to $223 million compared to the same period last year on higher pricing and favorable currency movements. Pricing rose as previously announced price increases took effect. Volumes declined largely for polyacetal ("POM") due to weakness in the automotive sector, primarily in Europe, and on reduced sales for lower-end applications.

Earnings from continuing operations before tax and minority interests decreased to $22 million from $26 million as higher pricing, cost savings and dividend income from cost investments did not fully offset $20 million in special charges, primarily for the impairment of the COC business, lower volumes and higher raw material costs. Equity in net earnings of affiliates remained relatively flat compared to last year. Earnings in 2004 included an $18 million charge for a non-cash inventory-related purchase accounting adjustment.

55




        Acetate Products


  Successor Successor  
in $ millions (except for percentages) Three Months
Ended June 30,
2005
Three Months
Ended June 30,
2004
Change in
$
Net sales   183     173     10  
Net sales variance:                  
    Volume   1            
    Price   5            
Operating profit   10     10      
Operating margin   5.5   5.8      
Special charges            
Earnings (loss) from continuing operations before
tax and minority interests
  12     14     (2
Depreciation and amortization   9     14     (5

    Three Months Ended June 30, 2005 Compared with Three Months Ended June 30, 2004

Net sales for Acetate Products increased by 6% to $183 million compared to the same period last year on higher pricing and volumes. Pricing increased for all business lines while volumes increased mainly on higher flake sales to the Company's recently expanded China tow ventures.

Earnings from continuing operations before tax and minority interests decreased to $12 million compared to $14 million in the same period last year. Higher pricing and savings from restructuring and productivity improvements were more than offset by increased raw material and energy costs as well as temporarily higher manufacturing costs, resulting from a realignment of production and inventory levels as part of the acetate restructuring strategy.

56




        Performance Products


  Successor Successor  
in $ millions (except for percentages) Three Months
Ended June 30,
2005
Three Months
Ended June 30,
2004
Change in
$
Net sales   47     45     2  
Net sales variance:                  
    Volume   2            
    Price   (3 )%             
    Currency   5            
Operating profit   15     2     13  
Operating margin   31.9   4.4      
Special charges            
Earnings (loss) from continuing operations before tax and
minority interests
  14     1     13  
Depreciation and amortization   3     2     1  

    Three Months Ended June 30, 2005 Compared with Three Months Ended June 30, 2004

Net sales for Performance Products increased by 4% to $47 million compared to the same period last year mainly as the result of favorable currency effects and modest volume increases. Pricing for Sunett ® sweetener declined, consistent with the Company's positioning strategy for the product while pricing for sorbates continued to improve.

Earnings from continuing operations before tax and minority interests increased to $14 million from $1 million last year, which included a $12 million charge for a non-cash inventory-related purchase accounting adjustment. The increase in earnings resulted from favorable currency movements, improved sorbates performance and productivity improvements.

57




        Other Activities

Other Activities primarily consists of corporate center costs, including financing and administrative activities, and certain other operating entities, including the captive insurance companies.

    Three Months Ended June 30, 2005 Compared with Three Months Ended June 30, 2004

Net sales for Other Activities decreased to $8 million from $11 million in the same quarter last year primarily due to the sale of PBI and the Vectran product lines in the second quarter of 2005. Loss from continuing operations before tax and minority interests improved to a loss of $74 million from a loss of $179 million in the same period last year. This was primarily due to the expensing in 2004 of $71 million in deferred financing costs for the prepayment of the senior subordinated bridge loan facilities. Also contributing to this decrease was a $40 million favorable change in our net foreign currency gain (loss) resulting from exchange rate movements and a change from a net asset to a net liability foreign currency position.

Summary of Consolidated Results — Three Months Ended June 30, 2005 Compared with Three Months Ended June 30, 2004

Net Sales

Net sales rose 23% to $1,517 million in the second quarter compared to the same period last year primarily on higher pricing (15%), mainly in the Chemical Products segment, sales of the recently acquired Vinamul emulsions business in February 2005 (8%), and favorable currency movements (2%). These increases were slightly offset by lower volumes (2%).

Gross Profit Margin

Gross profit margin increased to $342 million or 23% of sales in the three months ended June 30, 2005 from $171 million or 14% of sales in the comparable period last year. This increase primarily reflects significantly higher pricing and productivity improvements, primarily in Chemical Products, and the absence of a $49 million non-cash charge for the manufacturing profit added to inventory under purchase accounting which was charged to cost of sales. Higher raw material and energy costs partially offset these increases.

Selling, General and Administrative Expenses

Selling, general and administrative expense increased to $136 million compared to $125 million for the same period last year. This increase is primarily due to higher amortization expense of identifiable intangible assets acquired from CAG of $10 million as well the inclusion of the Vinamul emulsions business acquired in February 2005. These increases were partially offset by cost savings.

Special Charges

The components of special charges for the three months ended June 30, 2005 and 2004 were as follows:


  Successor Successor
  Three Months Ended
June 30, 2005
Three Months Ended
June 30, 2004
  (in $ millions)
Employee termination benefits   (7   (1
Plant/office closures        
Total Restructuring   (7   (1
Asset impairments   (24    
Insurance recoveries associated with plumbing cases   4     2  
Total Special Charges   (27   1  

Special charges increased to $27 million compared to income of $1 million for the same period last year. This increase was primarily due an additional impairment charge associated with revised estimates related to the Company's decision to divest its cyclo-olefin copolymer ("COC") business.

58




Operating Profit

Operating profit rose significantly to $152 million versus $25 million last year on margin expansion principally driven by higher pricing and productivity improvements. The effects more than offset higher raw material and energy costs, mainly for ethylene and natural gas, and higher special charges. Operating profit in 2004 included a $49 million charge for a non-cash inventory-related purchase accounting adjustment.

Equity in Net Earnings of Affiliates

Equity in net earnings of affiliates decreased by $6 million to $12 million for the three months ended June 30, 2005, compared to the same period last year. This decrease is primarily due to an impairment charge of $10 million related to the Estech GmbH & Co. KG venture, a producer of neopolyol esters in Oberhausen, Germany. Cash distributions received from equity affiliates increased to $10 million for the three months ended June 30, 2005, compared to $6 million in the same period of 2004.

Interest Expense

Interest expense decreased to $68 million for the three months ended June 30, 2005 from $130 million in the same period last year as interest expense in 2004 included $71 million of deferred financing costs for the prepayment of the senior subordinated bridge loan facilities. This decrease was slightly offset by increased interest on higher debt levels.

Interest Income

For the three months ended June 30, 2005, interest income increased by $2 million to $9 million compared to the same period in the prior year.

Other Income (Expense), Net

Other income (expense), net increased to $18 million of income for the three months ended June 30, 2005, compared to expense of $24 million for the comparable period last year. This increase is primarily due to a favorable change of $40 million in our net foreign currency gain (loss) resulting from exchange rate movements and a change from a net asset to a net liability foreign currency position. This increase was partially offset by expenses associated with the anticipated guaranteed payment to CAG minority shareholders of $7 million. Dividend income accounted for under the cost method remained flat at $7 million for the three months ended June 30, 2005, compared to the same period in 2004.

Income Taxes

Income taxes for the three months ended June 30, 2005 and 2004, are recorded based on the estimated annual effective tax rate. As of June 30, 2005, the estimated annualized tax rate for 2005 is 35%, which is slightly less than the combination of the statutory rate and state income tax rates in the U.S. The estimated annual effective tax rate for 2005 reflects earnings in low tax jurisdictions, a valuation allowance for the tax benefit associated with projected U.S. losses (which includes expenses associated with the early redemption of debt), and tax expense in certain non-U.S. jurisdictions. For the three months ended June 30, 2004, a tax expense of $10 million was recorded which resulted in a tax rate of negative 10%. This effective tax rate was primarily affected by the non-recognition of tax benefits associated with acquisition related expenses.

Earnings (Loss) from Discontinued Operations

Earnings from discontinued operations was $0 million for the three months ended June 30, 2005 compared to a loss of $1 million from the comparable period last year. The loss in the three months ended June 30, 2004 reflected a purchase price adjustment related to the sale of the nylon business.

Net Earnings (Loss)

As a result of the factors mentioned above, the Company had net earnings of $67 million in the three months ended June 30, 2005, compared to a net loss of $125 million in the same period last year.

59




Selected Data by Business Segment –Three Months Ended March 31, 2005 Compared with Three Months Ended March 31, 2004


  Successor Predcessor  
  Three
Months
Ended
March 31,
2005
Three
Months
Ended
March 31,
2004
Change in
$
  (in $ millions)  
Net Sales                  
Chemical Products   1,044     818     226  
Technical Polymers Ticona   239     227     12  
Acetate Products   196     172     24  
Performance Products   47     44     3  
Segment Total   1,526     1,261     265  
Other Activities   12     11     1  
Intersegment Eliminations   (29   (29    
Total Net Sales   1,509     1,243     266  
                   
Special Charges                  
Chemical Products   (1   (1    
Technical Polymers Ticona   (1   (1    
Acetate Products   (1       (1
Performance Products            
Segment Total   (3   (2   (1
Other Activities   (35   (26   (9
Total Special Charges   (38   (28   (10
                   
Operating Profit (Loss)                  
Chemical Products   177     65     112  
Technical Polymers Ticona   39     31     8  
Acetate Products   20     9     11  
Performance Products   13     11     2  
Segment Total   249     116     133  
Other Activities   (83   (64   (19
Total Operating Profit   166     52     114  
                   
Earnings (Loss) from Continuing Operations
Before Tax and Minority Interests
                 
Chemical Products   193     64     129  
Technical Polymers Ticona   51     45     6  
Acetate Products   20     9     11  
Performance Products   12     11     1  
Segment Total   276     129     147  
Other Activities   (253   (57   (196
Total Earnings from Continuing Operations
Before Tax and Minority Interests
  23     72     (49

60




Selected Data by Business Segment –Three Months Ended March 31, 2005 Compared with Three Months Ended March 31, 2004 (Continued)


  Successor Predecessor  
  Three
Months
Ended
March 31,
2005
Three
Months
Ended
March 31,
2004
Change in
$
  (in $ millions)  
Depreciation & Amortization                  
Chemical Products   34     39     (5
Technical Polymers Ticona   15     16     (1
Acetate Products   9     13     (4
Performance Products   3     2     1  
Segment Total   61     70     (9
Other Activities   2     2      
Total Depreciation & Amortization   63     72     (9

Factors Affecting First Quarter 2005 Segment Sales Compared to First Quarter 2004


in percent Volume Price Currency Other* Total
Chemical Products   (1 )%    22   3   4   28
Technical Polymers Ticona   2         3         5  
Acetate Products   11     3             14  
Performance Products   9     (7   5         7  
Segment Total   2   15   2   2   21
* Primarily represents sales of the recently acquired Vinamul emulsion business

61




Summary by Business Segment—Three Months Ended March 31, 2005 Compared with Three Months Ended March 31, 2004

        Chemical Products


  Successor Predecessor  
in $ millions (except for percentages) Three Months
Ended March 31,
2005
Three Months
Ended March 31,
2004
Change in
$
Net sales   1,044     818     226  
Net sales variance:                  
     Volume   (1 )%             
     Price   22            
     Currency   3            
     Other   4            
Operating profit   177     65     112  
Operating margin   17.0   7.9      
Special charges   (1   (1    
Earnings (loss) from continuing operations before tax and
minority interests
  193     64     129  
Depreciation and amortization   34     39     (5

    Three Months Ended March 31, 2005 Compared with Three Months Ended March 31, 2004

Chemical Products' net sales increased 28% to $1,044 million compared to the same period last year mainly on higher pricing, segment composition changes, of which $66 million was related to the Vinamul emulsions acquisition, and favorable currency effects. Pricing increased for most products, driven by continued strong demand and high utilization rates across the chemical industry.

Earnings from continuing operations before tax and minority interests increased to $193 million from $64 million in the same period last year as higher pricing was partially offset by higher raw material costs. Earnings also benefited from an increase of $9 million in dividends from our methanol cost investment, which totaled $12 million in the quarter.

62




        Technical Polymers Ticona


  Successor Predecessor  
in $ millions (except for percentages) Three Months
Ended March 31,
2005
Three Months
Ended March 31,
2004
Change in
$
Net sales   239     227     12  
Net sales variance:                  
    Volume   2            
    Currency   3            
Operating profit   39     31     8  
Operating margin   16.3   13.7      
Special charges   (1   (1    
Earnings (loss) from continuing operations before tax
and minority interests
  51     45     6  
Depreciation and amortization   15     16     (1

    Three Months Ended March 31, 2005 Compared with Three Months Ended March 31, 2004

Net sales for Ticona increased by 5% to $239 million compared to the same period last year due to favorable currency effects and slightly higher volumes. Volumes increased for most product lines due to the successful introduction of new applications, which outweighed declines in polyacetal volumes resulting from the Company's focus on high-end business and decreased sales to European automotive customers. Overall pricing remained flat quarter over quarter as successfully implemented price increases were offset by lower average pricing for certain products due to the commercialization of lower cost grades for new applications.

Earnings from continuing operations before tax and minority interests increased 13% to $51 million as the result of cost savings from a recent restructuring, the favorable effects of a planned maintenance turnaround as well as slightly higher volumes. These increases were partially offset by higher raw material and energy costs.

63




        Acetate Products


  Successor Predecessor  
in $ millions (except for percentages) Three Months
Ended March 31,
2005
Three Months
Ended March 31,
2004
Change in
$
Net sales   196     172     24  
Net sales variance:                  
    Volume   11            
    Price   3            
Operating profit   20     9     11  
Operating margin   10.2   5.2      
Special charges   (1       (1
Earnings (loss) from continuing operations before
tax and minority interests
  20     9     11  
Depreciation and amortization   9     13     (4

    Three Months Ended March 31, 2005 Compared with Three Months Ended March 31, 2004

Net sales for Acetate Products increased by 14% to $196 million compared to the same quarter last year on higher volumes and pricing. Flake volumes increased mainly as a result of demand from Company ventures in China that recently completed tow capacity expansions. Filament volumes rose in anticipation of the Company's plans to exit this business by the end of the second quarter. Pricing increased for all business lines to cover higher raw material costs.

Earnings from continuing operations before tax and minority interests more than doubled from $9 million in first quarter last year to $20 million this year due to increased volumes, pricing and productivity improvements, which more than offset higher raw material and energy costs. Earnings also benefited from $4 million in lower depreciation and amortization expense largely as a result of previous impairments related to a major restructuring, which was partly offset by $3 million of expense for an asset retirement obligation.

64




        Performance Products


  Successor Predecessor  
in $ millions (except for percentages) Three Months
Ended March 31,
2005
Three Months
Ended March 31,
2004
Change in
$
Net sales   47     44     3  
Net sales variance:                  
    Volume   9            
    Price   (7 )%             
    Currency   5            
Operating profit   13     11     2  
Operating margin   27.7   25.0      
Special charges            
Earnings (loss) from continuing operations before tax and
minority interests
  12     11     1  
Depreciation and amortization   3     2     1  

    Three Months Ended March 31, 2005 Compared with Three Months Ended March 31, 2004

Net sales for the Performance Products segment increased by 7% to $47 million compared to the same period last year mainly on higher volumes, which more than offset lower pricing. Favorable currency movements also contributed to the sales increase. Higher volumes for Sunett sweetener reflected strong growth from new and existing applications in the U.S. and European beverage and confectionary markets. Pricing for Sunett declined on lower unit selling prices associated with higher volumes to major customers. Pricing for sorbates continued to recover, although worldwide overcapacity still prevailed in the industry.

Earnings from continuing operations before tax and minority interests increased to $12 million from $11 million in the same quarter last year. Strong volumes for Sunett, as well as favorable currency movements and cost savings, more than offset lower pricing for the sweetener. A primary European and U.S. production patent for Sunett expired at the end of March 2005.

        Other Activities

Other Activities primarily consists of corporate center costs, including financing and administrative activities, and certain other operating entities, including the captive insurance companies.

    Three Months Ended March 31, 2005 Compared with Three Months Ended March 31, 2004

Net sales for Other Activities increased slightly to $12 million from $11 million in the same quarter last year. Loss from continuing operations before tax and minority interests increased to $253 million from a loss of $57 million in the same period last year, largely due to $169 million of higher interest expense due to refinancing costs, increased debt levels, and higher interest rates. The loss includes $45 million of expenses for sponsor monitoring and related cancellation fees compared to special charges of $25 million in the same period last year for advisory services related to the tender offer of CAG.

65




Summary of Consolidated Results — Three Months Ended March 31, 2005 Compared with Three Months Ended March 31, 2004

Net Sales

Net sales rose 21% to $1,509 million in the first quarter compared to the same period last year primarily on higher pricing of 15%, mainly in the Chemical Products segment. Favorable currency movements, higher volumes, and a composition change in the Chemical Products segment each increased net sales by 2%.

The segment composition changes consisted of the acquisition of the Vinamul emulsions business in February 2005, which was partly offset by the effects of a contract manufacturing arrangement under which certain acrylates products are now being sold. Only the margin realized under the contract manufacturing arrangement is reported in net sales.

Gross Profit Margin

Gross profit margin increased to $384 million or 25% of sales in the three months ended March 31, 2005 from $241 million or 19% of sales in the comparable period last year. This increase primarily reflects significantly higher pricing, primarily in Chemical Products, lower depreciation expense and productivity improvements. Higher raw material and energy costs partially offset these increases.

Selling, General and Administrative Expenses

Selling, general and administrative expense increased to $161 million compared to $137 million for the same period last year. This increase is primarily due to expenses for sponsor monitoring services of $10 million, higher amortization expense of identifiable intangible assets acquired of $10 million as well as higher professional costs primarily related to compliance with Section 404 of the Sarbanes-Oxley Act of 2002.

Special Charges

The components of special charges for the three months ended March 31, 2005 and 2004 were as follows:


  Successor Predecessor  
  Three Months Ended
March 31, 2005
Three Months Ended
March 31, 2004
Change in $
  (in $ millions)
Employee termination benefits   (2   (2    
Plant/office closures   (1       (1
Total restructuring   (3   (2   (1
Termination of advisor monitoring services   (35       (35
Advisory services       (25   25  
Other       (1   1  
Total special charges   (38   (28   (10

Operating Profit

Operating profit increased to $166 million in the quarter compared to $52 million in the same period last year on gross margin expansion of $143 million, as significantly higher pricing, primarily in Chemical Products, lower depreciation expense and productivity improvements more than offset higher raw material and energy costs. Operating profit also benefited from increased volumes in Acetate Products, Performance Products and Ticona. Depreciation and amortization expense declined by $9 million as decreases in depreciation resulting from purchase accounting adjustments, more than offset increased amortization expense for acquired intangible assets.

66




Equity in Net Earnings of Affiliates

Equity in net earnings of affiliates rose by $3 million to $15 million for the three months ended March 31, 2005, compared to the same period last year. Cash distributions received from equity affiliates increased to $36 million for the three months ended March 31, 2005, compared to $16 million in the same period of 2004. The increase in cash distributions is mainly due to strong business conditions in 2004 for Ticona's high performance product ventures and Chemical Products' methanol venture and the timing of dividend payments.

Interest Expense

Interest expense increased to $176 million for the three months ended March 31, 2005 from $6 million in the same period last year, primarily due to expenses of $102 million including early redemption premiums and deferred financing costs associated with the refinancing that occurred in the first quarter of 2005. Higher debt levels resulting primarily from the acquisition of CAG and higher interest rates also increased interest expense.

Interest Income

For the three months ended March 31, 2005, interest income increased by $10 million to $15 million compared to the same period in the prior year, primarily due to higher average cash levels.

Other Income (Expense), Net

Other income (expense), net decreased to $3 million of income for the three months ended March 31, 2005, compared to $9 million for the comparable period last year. This decrease is primarily due to expenses associated with the anticipated guaranteed payment to CAG minority shareholders and the ineffective portion of a net investment hedge. These decreases were partially offset by higher dividends from cost investments. Dividend income accounted for under the cost method increased by $8 million to $14 million for the three months ended March 31, 2005, compared to the same period in 2004. The increase in the first quarter of 2005 primarily resulted from the timing of receipt of dividends.

Income Taxes

Income taxes for the three months ended March 31, 2005 and 2004, are recorded based on the estimated annual effective tax rate. As of March 31, 2005, the estimated annualized tax rate for 2005 is 35%, which is slightly less than the combination of the statutory rate and state income tax rates in the U.S. The estimated annual effective tax rate for 2005 reflects earnings in low tax jurisdictions, a valuation allowance for the tax benefit associated with projected U.S. losses (which includes expenses associated with the early redemption of debt), and tax expense in certain non-U.S. jurisdictions. The Predecessor had an effective tax rate of 24% for the three months ended March 31, 2004, compared to the German statutory rate of 40%, which was primarily affected by earnings in low tax jurisdictions.

Earnings from Discontinued Operations

Earnings from discontinued operations was $0 million for the three months ended March 31, 2005 compared to $23 million from the comparable period last year. Earnings in 2004 reflected a gain and tax benefit recognized in 2004 associated with the sale of the acrylates business. The tax benefit is mainly attributable to the utilization of a capital loss carryover benefit that had been previously subject to a valuation allowance.

For the three months ended March 31, 2004, the Chemical Products segment had net sales of $21 million and an operating loss of $5 million.

Net Earnings

As a result of the factors mentioned above, net earnings decreased by $88 million to a net loss of $10 million in the three months ended March 31, 2005, compared to the same period last year.

67




Outlook

For the second half of the year, the Company expects that global GDP will remain strong and that pricing could be impacted as the acetyls market absorbs the industry capacity expansions planned for the second half of 2005. The Company also expects the Acetex acquisition to be accretive in the second half of 2005.

For the remainder of the year, the Company expects to incur expenses and cash outlays for the restructuring of its businesses and product portfolio, cost improvement and focused growth in core areas.

Liquidity and Capital Resources

Cash Flows

Net Cash Provided by/(Used in) Operating Activities

Cash flow from operating activities increased to a cash inflow of $190 million for the six months ended June 30, 2005 compared to a cash outflow of $214 million for the same period last year. This increase primarily resulted from the contribution of an increase in operating profit in 2005 of $241 million, the payment of a $95 million obligation to a third party in 2004, the absence of payments associated with stock appreciation rights of $59 million, recoveries from an insurance provider related to the plumbing matters of $44 million in 2005, a decrease in pension contributions of $125 million and an increase in dividends received from cost and equity investments of $32 million. These increases were partially offset by higher interest payments and contributions to the non-qualified pension plan's rabbi trusts of $63 million in 2005. Unfavorable foreign currency effects on the euro versus the U.S. dollar on cash and cash equivalents increased to $99 million from $27 million in the same period last year.

Net Cash Provided by/(Used in) Investing Activities

Net cash from investing activities improved to a cash outflow of $138 million in the six months ended June 30, 2005 compared to a cash outflow of $1,553 million for the same period last year. The cash outflow in 2004 resulted from the CAG acquisition. The 2005 cash outflow included the acquisition of the Vinamul emulsions business and a decrease in net proceeds from disposal of discontinued operations of $64 million. These items were partially offset by an increase in cash inflows related to net sales of marketable securities of $83 million. The net proceeds from the disposal of discontinued operations represents cash received in 2005 from an early contractual settlement of receivables of $75 million related to the sale in 2000 of the Predecessor's interest in Vinnolit Kunstoff GmbH and Vintron GmbH while the net proceeds of $139 million in the same period last year represented the net proceeds from the sale of the acrylates business. Capital expenditures on property, plant and equipment decreased to $86 million from $94 million in 2004.

Net Cash Provided by/(Used in) Financing Activities

Net cash from financing activities decreased to a cash inflow of $168 million for the six months ended June 30, 2005 compared to a cash inflow of $2,455 million in the same period last year. The cash inflow in 2004 primarily reflected higher net proceeds from borrowings in connection with the acquisition of CAG. Major financing activities for 2005 are as follows:

•  Borrowings under the term loan facility of $1,135 million.
•  Distribution to Series B shareholders of $804 million.
•  Redemption and related premiums of the senior subordinated notes of $572 million and senior discount notes of $207 million.
•  Proceeds from the issuances of common stock, net of $752 million and preferred stock, net of $233 million.

68




•  Repayment of floating rate term loan, including related premium, of $354 million.

Refer to the Liquidity Section for more information.

Liquidity

Our contractual obligations, commitments and debt service requirements over the next several years are significant and are substantially higher than historical amounts. Our primary source of liquidity will continue to be cash generated from operations as well as existing cash on hand. We believe we will have available resources to meet both our short-term and long-term liquidity requirements, including debt service. If our cash flow from operations is insufficient to fund our debt service and other obligations, we may be forced to use other means available to us such as to increase our borrowings under our lines of credit, reduce or delay capital expenditures, seek additional capital or seek to restructure or refinance our indebtedness.

In January 2005, we completed an initial public offering of Series A common stock and received net proceeds of approximately $752 million after deducting underwriters' discounts and offering expenses of $48 million. Concurrently, the Company received net proceeds of $233 million from the offering of its convertible preferred stock and borrowed an additional $1,135 million under the amended and restated senior credit facilities. A portion of the proceeds of the share offerings were used to redeem $188 million of senior discount notes and $521 million of senior subordinated notes, which excludes early redemption premiums of $19 million and $51 million, respectively. We also used a portion of the proceeds from additional borrowings under our senior credit facilities to repay our $350 million floating rate term loan, which excludes a $4 million early redemption premium, and used $200 million of the proceeds as the primary financing for the acquisition of the Vinamul emulsion business.

On April 7, 2005, we used the remaining proceeds to pay a special cash dividend to holders of the Company's Series B common stock of $804 million. Upon payment of the $804 million dividend, all of the outstanding shares of Celanese Series B common stock converted automatically to shares of Celanese Series A common stock. In addition, we may use the available sources of liquidity to purchase the remaining outstanding shares of Celanese AG.

As a result of the offerings in January 2005, we now have $240 million aggregate liquidation preference of outstanding preferred stock. Holders of the preferred stock are entitled to receive, when, as and if, declared by our board of directors, out of funds legally available therefor, cash dividends at the rate of 4.25% per annum (or $1.06 per share) of liquidation preference, payable quarterly in arrears, which commenced on May 1, 2005. Dividends on the preferred stock are cumulative from the date of initial issuance. This dividend is expected to result in an annual dividend payment of $10 million. Accumulated but unpaid dividends accumulate at an annual rate of 4.25%. The preferred stock is convertible, at the option of the holder, at any time into shares of our Series A common stock at a conversion rate of 1.25 shares of our Series A common stock per $25.00 liquidation preference of the preferred stock. As of August 11, 2005 the Company has paid $5 million in aggregate dividends on its preferred stock.

During July 2005, our board of directors adopted a policy of declaring, subject to legally available funds, a quarterly cash dividend on each share of our Series A common stock at an annual rate initially equal to approximately 1% of the $16.00 initial public offering price per share of our Series A common stock (or $0.16 per share) unless our board of directors in its sole discretion determines otherwise. On August 11, 2005 the first such cash dividend payment of $0.04 per share ($6 million) on the Company's Series A common stock was made. Based upon the number of outstanding shares as of June 30, 2005, the anticipated annual cash dividend payment is $25 million. However, there is no assurance that sufficient cash or surplus will be available to pay such dividend.

In July 2005, the Company acquired Acetex Corporation ("Acetex") for $270 million and assumed Acetex's $235 million of debt, which is net of cash acquired of $66 million. Acetex's operations include an acetyls business with plants in Europe and a North-American specialty polymers and film business. Acetex also previously concluded an agreement for a venture to build an acetyls

69




complex in Saudi Arabia and has commenced the technical planning for this facility. The Company acquired Acetex using existing cash. The Company had Acetex exercise its option to redeem its 10 7/8% senior notes due 2009 totaling approximately $265 million. The redemption will be funded primarily with cash on hand and is expected to take place August 19, 2005. The redemption price is expected to be approximately $280 million, which represents 105.438% of the outstanding principal amount, plus accrued and unpaid interest to August 19, 2005.

As of June 30, 2005, the Company had total debt of $3,393 million and cash and cash equivalents of $959 million. Net debt (total debt less cash and cash equivalents) decreased to $2,434 million from $2,549 million as of December 31, 2004 due to an increase in cash and cash equivalents of $121 million primarily from cash provided from operations.

The Company is in compliance with all of its covenant agreements as of June 30, 2005.

Contractual Obligations.     The following table sets forth our fixed contractual debt obligations as of June 30, 2005:


Fixed Contractual Debt Obligations Total Remaining
2005
2006-2007 2008- 2009 2010
and thereafter
  (in $ millions)
Senior Credit Facilities — Term Loans Facility   1,725     9     34     33     1,649  
Senior Subordinated Notes (1)   953                 953  
Senior Discount Notes (2)   554                 554  
Other Debt (3)   354     94     41     22     197  
Total Fixed Contractual Debt Obligations   3,586     103     75     55     3,353  
(1) Does not include $4 million of premium on the $225 million of the senior subordinated notes issued July 1, 2004.
(2) Reflects the accreted value of the notes at maturity.
(3) Does not include $2 million purchase accounting adjustment resulting from acquisition of CAG.

Senior Credit Facilities.     As of June 30, 2005, the senior credit facilities of $2,553 million consist of a term loan facility, a revolving credit facility, and a credit-linked revolving facility.

Subsequent to the consummation of the initial public offering in January 2005, we entered into amended and restated senior credit facilities which increased the term facility. The terms of the amended and restated senior credit facilities are substantially similar to the terms of our immediately previous senior credit facilities. As of June 30, 2005, the term loan facility had a balance of $1,725 million (including approximately €275 million), which matures in 2011. In addition, there was a $242 million delayed draw facility which expired unutilized in July 2005.

The revolving credit facility, through a syndication of banks, provides for borrowings of up to $600 million, including the availability of letters of credit in U.S. dollars and euros and for borrowings on same-day notice.

In January 2005, the revolving credit facility was increased from $380 million to $600 million under the amended and restated senior credit facilities. The $228 million credit-linked revolving facility, which matures in 2009, includes borrowing capacity available for letters of credit. As of July 31, 2005, there were $226 million of letters of credit issued under the credit-linked revolving facility. As of July 31, 2005, there was $58 million of letters of credit issued under the revolving credit facility. As of July 31, 2005, $544 million remained available for borrowing under the revolving credit facilities (taking into account letters of credit issued under the credit-linked revolving facility).

Senior Subordinated Notes.     In February 2005, we used approximately $521 million of the net proceeds of the offering of our Series A common stock to redeem a portion of the senior subordinated notes and $51 million to pay the premium associated with the early redemption. As of June 30, 2005, the senior subordinated notes, excluding $4 million of premiums, consist of $796 million of 9 5/8% Senior Subordinated Notes due 2014 and €130 million of 10 3/8% Senior Subordinated Notes

70




due 2014. All of BCP Crystal's U.S. domestic, wholly owned subsidiaries that guarantee BCP Crystal's obligations under the senior credit facilities guarantee the senior subordinated notes on an unsecured senior subordinated basis.

Senior Discount Notes.     In September 2004, Crystal LLC and Crystal US Sub 3 Corp., a subsidiary of Crystal LLC, issued $853 million aggregate principal amount at maturity of their senior discount notes due 2014 consisting of $163 million principal amount at maturity of their 10% Series A senior discount notes due 2014 and $690 million principal amount at maturity of their 10½% Series B Senior Discount Notes due 2014 (collectively, the "senior discount notes"). The gross proceeds of the offering were $513 million. Approximately $500 million of the proceeds were distributed to the Company's Original Shareholders, with the remaining proceeds used to pay fees associated with the refinancing. Until October 1, 2009, interest on the senior discount notes will accrue in the form of an increase in the accreted value of such notes. Cash interest on the senior discount notes will accrue commencing on October 1, 2009 and be payable semiannually in arrears on April 1 and October 1. In February 2005, we used approximately $37 million of the net proceeds of the offering of our Series A common stock to redeem a portion of the Series A senior discount notes and $151 million to redeem a portion of the Series B senior discount notes and $19 million to pay the premium associated with the early redemption. As of June 30, 2005, there were $554 million aggregate principal amount at maturity outstanding, consisting of $106 million principal amount at maturity of their 10% Series A senior discount notes due 2014 and $448 million principal amount at maturity of their 10½% Series B Senior Discount Notes due 2014.

Other Debt.     Other debt of $354 million, which does not includes a $2 million reduction under purchase accounting, is primarily made up of fixed rate pollution control and industrial revenue bonds, short-term borrowings from affiliated companies and capital lease obligations.

Off-Balance Sheet Arrangements

We have not entered into any material off-balance sheet arrangements.

Recent Accounting Pronouncements

See Note 5 to the Unaudited Interim Consolidated Financial Statements included in this Form 10-Q for discussion of recent accounting pronouncements.

Critical Accounting Policies and Estimates

The preparation of the Company's consolidated financial statements requires management to apply accounting principles generally accepted in the United States of America to the Company's specific circumstances and make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements, the disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

There have been no material revisions to the critical accounting policies as filed in the Company's Annual Report on Form 10-K for the nine months ended December 31, 2004 with the Securities and Exchange Commission on March 31, 2005.

During the six months ended June 30, 2005, the Company recorded asset impairments primarily consisting of revised estimates related to the Company's decision to divest its COC business. The Company also increased goodwill by $20 million associated with purchase accounting adjustments related to the acquisition of CAG.

Forward-Looking Statements May Prove Inaccurate

This Quarterly Report contains certain forward-looking statements and information relating to us that are based on the beliefs of our management as well as assumptions made by, and information currently available to, us. These statements include, but are not limited to, statements about our strategies, plans, objectives, expectations, intentions, expenditures, and assumptions and other

71




statements contained in this prospectus that are not historical facts. When used in this document, words such as "anticipate," "believe," "estimate," "expect," "intend," "plan" and "project" and similar expressions, as they relate to us are intended to identify forward-looking statements. These statements reflect our current views with respect to future events, are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Further, certain forward-looking statements are based upon assumptions as to future events that may not prove to be accurate.

Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. These factors include, among other things:

•  changes in general economic, business, political and regulatory conditions in the countries or regions in which we operate;
•  the length and depth of product and industry business cycles particularly in the automotive, electrical, electronics and construction industries;
•  changes in the price and availability of raw materials, particularly changes in the demand for, supply of, and market prices of fuel oil, natural gas, coal, electricity and petrochemicals such as ethylene, propylene and butane, including changes in production quotas in OPEC countries and the deregulation of the natural gas transmission industry in Europe;
•  the ability to pass increases in raw material prices on to customers or otherwise improve margins through price increases;
•  the ability to maintain plant utilization rates and to implement planned capacity additions and expansions;
•  the ability to reduce production costs and improve productivity by implementing technological improvements to existing plants;
•  the existence of temporary industry surplus production capacity resulting from the integration and start-up of new world-scale plants;
•  increased price competition and the introduction of competing products by other companies;
•  the ability to develop, introduce and market innovative products, product grades and applications, particularly in the Ticona and Performance Products segments of our business;
•  changes in the degree of patent and other legal protection afforded to our products;
•  compliance costs and potential disruption or interruption of production due to accidents or other unforeseen events or delays in construction of facilities;
•  potential liability for remedial actions under existing or future environmental regulations;
•  potential liability resulting from pending or future litigation, or from changes in the laws, regulations or policies of governments or other governmental activities in the countries in which we operate;
•  changes in currency exchange rates and interest rates;
•  changes in the composition or restructuring of us or our subsidiaries and the successful completion of acquisitions, divestitures and venture activities;
•  pending or future challenges to the Domination Agreement; and
•  various other factors, both referenced and not referenced in this document.

Many of these factors are macroeconomic in nature and are, therefore, beyond our control. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from those described in this Quarterly Report as anticipated, believed, estimated, expected, intended, planned or projected. We neither intend nor assume any obligation to update these forward-looking statements, which speak only as of their dates.

72




Item 3.    Quantitative and Qualitative Disclosures about Market Risk

Market risk for our Company has not changed significantly from the foreign exchange, interest rate, and commodity risks disclosed in Item 7A of our Annual Report on Form 10-K for the nine months ended December 31, 2004, with the exception of the following:

The Company entered into an interest rate swap with a notional amount of $300 million to reduce its exposure to fluctuations in interest rates associated with a portion of the term loans borrowed under our senior credit facilities. This interest rate swap was designated as a cash flow hedge. The fair value of the swap as of June 30, 2005 was a liability of $12 million, which includes accrued interest of $4 million.

Item 4.    Controls and Procedures

On March 30, 2005, we received a letter from KPMG LLP ("KPMG"), our independent auditors, in connection with the audit of our financial statements as of and for the nine months ended December 31, 2004, which identified two material weaknesses in our internal controls for the same period, both of which continued during the period covered by this Quarterly Report. The first material weakness related to several deficiencies in the assessment of hedge effectiveness and documentation. The required adjustments were made in the proper accounting period, except for one hedging transaction adjusted during the period covered by this Quarterly Report. We do not believe that these adjustments had any material impact on previously reported financial information. The second material weakness related to conditions preventing our ability to adequately research, document, review and draw conclusions on accounting and reporting matters, which had previously resulted in adjustments that had to be recorded to prevent our financial statements from being materially misleading. The conditions largely related to significant increases in the frequency of, and the limited amount of time and technical accounting resources available to address, complex accounting matters and transactions and as a result of the consummation of simultaneous debt and equity offerings during the year-end closing process. In response to the letter from KPMG with respect to the first material weakness identified above, during the period covered by our Quarterly Report on Form 10-Q for the quarter ended March 31, 2005, we organized a team responsible for the identification and documentation of potential derivative accounting transactions and commenced formal training for team members specifically related to derivative accounting. In addition, with respect to the second material weakness identified above, during the six-month period ended June 30, 2005, we endeavored to ensure that adequate time was made available for company personnel to adequately research, document, review and conclude on accounting and reporting matters and to increase accounting resources. Despite our efforts, conditions relating to the material weaknesses identified above continued during the period covered by this Quarterly Report. We are continuing our efforts to implement these initiatives, which have materially affected and are reasonably likely to affect materially our internal controls over financial reporting.

Celanese, under the supervision and with the participation of Celanese's management, including the chief executive officer (CEO) and chief financial officer (CFO), performed an evaluation of the effectiveness of Celanese's "disclosure controls and procedures" (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the "34 Act")) as of June 30, 2005. Disclosure controls and procedures are defined as controls and other procedures of an issuer that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the 34 Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission ("SEC"). Based on this evaluation, and as a result of the material weakness that was identified and continued during the period covered by this Quarterly Report, Celanese's CEO and CFO concluded that, as of June 30, 2005, the end of the period covered by this Quarterly Report, Celanese's disclosure controls and procedures were not effective for gathering, analyzing and disclosing the material information Celanese is required to disclose in the reports it files under the 34 Act, within the time periods specified in the rules and forms of the SEC. Except as discussed above, there have been no changes in Celanese's "internal controls over financial reporting" (as defined in Rule 13a-15(f) under the 34 Act) during the period covered by this Quarterly Report that have materially affected or are reasonably likely to materially affect, internal controls over financial reporting.

73




PART II — OTHER INFORMATION

Item 1.    Legal Proceedings

We are involved in a number of legal proceedings, lawsuits and claims incidental to the normal conduct of our business, relating to such matters as product liability, antitrust, past waste disposal practices and release of chemicals into the environment. While it is impossible at this time to determine with certainty the ultimate outcome of these proceedings, lawsuits and claims, management believes that adequate provisions have been made and that the ultimate outcomes will not have a material adverse effect on our financial position, but may have a material adverse effect on the results of operations or cash flows in any given accounting period. See also Note 12 to the Unaudited Interim Consolidated Financial Statements.

Plumbing Actions

No material developments regarding this matter, previously reported in the Annual Report on Form 10-K for the year ended December 31, 2004, and in the Quarterly Report on Form 10-Q for the three months' ended March 31, 2005, occurred during the second quarter of 2005. For a summary of the history and current status of these matters, see Note 12 to the Unaudited Interim Consolidated Financial Statements.

Sorbates Antitrust Actions

No material developments regarding this matter, previously reported in the Annual Report on Form 10-K for the year ended December 31, 2004, occurred during the second quarter of 2005, except as set forth below. For a summary of the history and current status of these matters, see Note 12 to the Unaudited Interim Consolidated Financial Statements.

In January 2005, Hoechst, Nutrinova, and other subsidiaries, as well as other sorbates manufacturers entered into a settlement agreement with the Attorneys General of Connecticut, Florida, Hawaii, Maryland, South Carolina, Oregon and Washington. Pursuant to the terms of the settlement agreement, the defendants agreed to refrain from engaging in anticompetitive conduct with respect to the sale or distribution of sorbates and pay an immaterial amount to the states in satisfaction of all released claims.

Acetic Acid Patent Infringement Matters

No material developments regarding this matter, previously reported in the Annual Report on Form 10-K for the year ended December 31, 2004, occurred during the second quarter of 2005. For a summary of the history and current status of this matter, see Note 12 to the Unaudited Interim Consolidated Financial Statements.

Shareholder Litigation

During August 2004, nine actions were brought by minority shareholders against CAG in the Frankfurt District Court ( Landgericht ), all of which were consolidated in September 2004.

Several minority shareholders joined these proceedings via a third party intervention in support of the plaintiffs. The Purchaser has joined the proceedings via a third party intervention in support of CAG.

Among other things, these actions request the court to set aside shareholder resolutions passed at the extraordinary general meeting held on July 30 and 31, 2004 based on allegations that include the alleged violation of procedural requirements and information rights of the shareholders.

In a related matter, twenty-seven minority shareholders filed lawsuits in May and June of 2005 in the Frankfurt District Court ( Landgericht ) contesting the shareholder resolutions passed at the annual general meeting held May 19-20, 2005, which confirmed the resolutions passed at the July 30-31, 2004

74




extraordinary general meeting. The Frankfurt District Court ( Landgericht ) has suspended the proceedings regarding the resolutions passed at the July 30-31, 2004 extraordinary general meeting described above as long as the lawsuits contesting the confirmatory resolutions are pending. In addition, on May 9, 2005, one minority shareholder brought forward an additional action with the Frankfurt District Court ( Landgericht ) and requested the court rule that the shareholder resolutions passed at the extraordinary general meeting on July 30-31, 2004 were void based on allegations that certain formal requirements necessary in connection with the invitation to the extraordinary general meeting had been related. This action has not been suspended.

Further, on August 2, 2004, two minority shareholders instituted public register proceedings
with each of the Königstein Local Court ( Amtsgericht ) and the Frankfurt District Court ( Landgericht ), both with a view to have the registration of the Domination Agreement in the Commercial Register deleted ( Amtslöschungsverfahren ). These actions are based on an alleged violation of procedural requirements at the extraordinary general meeting, an alleged undercapitalization of the Purchaser and Blackstone and an alleged misuse of discretion by the competent court with respect to the registration of the Domination Agreement in the Commercial Register. In April 2005, the court of appeals rejected the demand by one shareholder for injunctive relief, and in June 2005 the Frankfurt District Court ( Landgericht ) ruled that it does not have jurisdiction over this matter. The claims in the Königstein Local Court ( Amtsgericht ) are still pending.

Based upon information available as of the date of this document, the outcome of the foregoing proceedings cannot be predicted with certainty. Except for certain challenges on limited grounds, the time period to bring forward challenges has expired.

The amounts of the fair cash compensation ( Abfindung ) and of the guaranteed fixed annual payment ( Ausgleich ) offered under the Domination Agreement may be increased in special award proceedings ( Spruchverfahren ) initiated by minority shareholders, which may further reduce the funds the Purchaser can otherwise make available to us. Several minority shareholders of CAG initiated special award proceedings seeking the court's review of the amounts of the fair cash compensation ( Abfindung ) and of the guaranteed fixed annual payment ( Ausgleich ) offered under the Domination Agreement. As a result of these proceedings, the amount of the fair cash consideration and the guaranteed fixed annual payment offered under the Domination Agreement could be increased by the court so that all minority shareholders, including those who have already tendered their shares into the mandatory offer and have received the fair cash compensation could claim the respective higher amounts. This could reduce the funds the Purchaser can make available to Celanese and its subsidiaries and, accordingly, diminish our ability to make payments on our indebtedness. However, the court dismissed all of these proceedings in March 2005 on the grounds of inadmissibility. The dismissal has been appealed.

In February 2005, a minority shareholder also brought a lawsuit against the Purchaser, as well as a former member of CAG's board of management and a former member of CAG's supervisory board, in the Frankfurt District Court ( Landgericht ). Among other things, this action seeks to unwind the tender of the plaintiff's shares in the Tender Offer and seeks compensation for damages suffered as a consequence of tendering shares in the Tender Offer. The court ruled against the plaintiff in this matter in June 2005. The plaintiff appealed this decision with respect to the Purchaser and the former member of the CAG board of management; however, with respect to the former member of the CAG supervisory board, the plaintiff has accepted the court's ruling.

Based upon the information as available, the outcome of the foregoing proceedings cannot be predicted with certainty.

Other Matters

As of June 30, 2005, Celanese Ltd. and/or CNA Holdings, Inc., both our U.S. subsidiaries, are defendants in approximately 680 asbestos cases. Because many of these cases involve numerous plaintiffs, we are subject to claims significantly in excess of the number of actual cases. We have reserves for defense costs related to claims arising from these matters. We believe we do not have any significant exposure in these matters.

75




Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds

On April 7, 2005, the Company issued 99,377,884 shares of Series A common stock to the holders of Series B common stock upon the conversion of such Series B common stock into Series A common stock. The conversion, which was in accordance with the Company's Second Amended and Restated Certificate of Incorporation, did not involve a public offering and was exempt from registration pursuant to Section 3(a)(9) of the Securities Act of 1993, as amended.

Item 3.    Defaults Upon Senior Securities

None.

Item 4.    Submission of Matters to a Vote of Security Holders

The 2005 annual meeting of shareholders of Celanese was held on June 1, 2005. At that annual meeting, each of the following directors was elected to serve a three-year term to expire at the 2008 annual meeting of shareholders: Dr. Hanns Ostmeier, James Quella and Daniel S. Sanders. The terms of the following directors continued after the 2005 annual meeting: John M. Ballbach, James Barlett, Chinh E. Chu, Benjamin J. Jenkins, Dr. William H. Joyce, Anjan Mukherjee, Paul H. O'Neill, and David N. Weidman.


Matters Submitted
For Shareholder Vote
For Against Withheld Abstentions Broker
Non-Votes
1.    Election of Class I Directors:                  
Dr. Hanns Ostmeier   37,339,958   N/A   8,460,924   N/A N/A
James Quella   37,232,370   N/A   8,568,512   N/A N/A
Daniel S. Sanders   43,227,004   N/A   2,573,878   N/A N/A
2.    Ratification of KPMG LLP as
        the Company's independent
        registered public accounting firm
        for the fiscal year ending
        December 31, 2005
  44,671,533   1,116,349   N/A   13,000 N/A
N/A — Not Applicable

Item 5.    Other Information

None.

Item 6.    Exhibits


Exhibit
Number
Description
3.1 Second Amended and Restated Certificate of Incorporation of Registrant (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K (File No. 001-32410) filed with the SEC on January 28, 2005)
3.2 Amended and Restated By-laws of Registrant (incorporated by reference to Exhibit 3.2 to the Registrant's Registration Statement on Form S-4 (File No. 333 - ) filed with the SEC on April 13, 2005).
3.3 Certificate of Designations of Convertible Perpetual Preferred Stock (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K (File No. 001-32410) filed with the SEC on January 28, 2005)
4.1 Form of certificate of Series A common stock (incorporated by reference to Exhibit 4.1 to Amendment No. 6 to the Registrant's Registration Statement on Form S-1 (File No. 333-120187) (the "Form S-1") filed with the SEC on January 19, 2005)

76





Exhibit
Number
Description
4.2 Form of certificate of Convertible Perpetual Preferred Stock (incorporated by reference to Exhibit 4.2 to Amendment No. 5 to the Form S-1 filed with the SEC on January 13, 2005)
4.3 Second Amended and Restated Shareholders' Agreement, dated as of January 18, 2005, among Celanese Corporation, Blackstone Capital Partners (Cayman) Ltd. 1, Blackstone Capital Partners (Cayman) Ltd. 2, Blackstone Capital Partners (Cayman) Ltd. 3 and BA Capital Investors Sidecar Fund, L.P. (incorporated by reference to Exhibit 10.1 to the Form 8-K (File No. 001-32410) filed with the SEC on January 28, 2005)
4.4 Amended and Restated Registration Rights Agreement, dated as of January 26, 2005, among Blackstone Capital Partners (Cayman) Ltd. 1, Blackstone Capital Partners (Cayman) Ltd. 2, Blackstone Capital Partners (Cayman) Ltd. 3, BA Capital Investors Sidecar Fund, L.P. and Celanese Corporation (incorporated by reference to Exhibit 10.2 to the Form 8-K (File No. 001-32410) filed with the SEC on January 28, 2005)
10.1 Offer letter agreement, effective as of April 1, 2005, between David A. Loeser and Celanese Corporation (incorporated by reference to Exhibit 10.22 to the Form 10-Q filed with the SEC on May 16, 2005)
10.2 Offer letter agreement, effective as of April 18, 2005, between Curtis S. Shaw and Celanese Corporation (incorporated by reference to Exhibit 10.23 to the Form 10-Q filed with the SEC on May 16, 2005)
12 Computation of ratio of earnings to fixed charges (filed herewith)
31.1 Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
31.2 Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
32.1 Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith)
32.2 Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith)

PLEASE NOTE: It is inappropriate for readers to assume the accuracy of, or rely upon any covenants, representations or warranties that may be contained in agreements or other documents filed as Exhibits to, or incorporated by reference in, this Quarterly Report. Any such covenants, representations or warranties may have been qualified or superseded by disclosures contained in separate schedules or exhibits not filed with or incorporated by reference in this Quarterly Report, may reflect the parties' negotiated risk allocation in the particular transaction, may be qualified by materiality standards that differ from those applicable for securities law purposes, and may not be true as of the date of this Quarterly Report or any other date and may be subject to waivers by any or all of the parties. Where exhibits and schedules to agreements filed or incorporated by reference as Exhibits hereto are not included in these exhibits, such exhibits and schedules to agreements are not included or incorporated by reference herein.

77




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


  CELANESE CORPORATION
  By: /s/ David N. Weidman                                        
    Name:    David N. Weidman
Title:    President and Chief Executive Officer
Date:    August 12, 2005
  By: /s/    Corliss J. Nelson                                            
    Name:    Corliss J. Nelson
Title:    Executive Vice President and Chief
   Financial Officer
   (Principal Financial Officer)
Date:    August 12, 2005

78




Exhibit 12

CELANESE CORPORATION
COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES


  Successor Predecessor
  Six Months
Ended
June 30, 2005
Three Months
Ended
June 30, 2005
Three Months
Ended
June 30,2004
Three Months
Ended
March 31, 2004
Earnings:      
Earnings (loss) from continuing operations before tax and minority interest   146     123     (104   72  
Less:      
Equity in net earnings of affiliates   (27   (12   (18   (12
Plus :      
Income distributions from equity investments   46     10     6     15  
Amortization of capitalized interest   3     1     2     2  
Total fixed charges   277     84     137     16  
Total earnings as defined before combined fixed charges   445     206     23     93  
Fixed charges:      
Interest expense   244     68     130     6  
Capitalized interest   2     1     1     3  
Estimated interest portion of rent expense   12     6     6     7  
Cumulative undeclared and declared preferred stock dividends   4     2          
Guaranteed payment to minority shareholders   15     7          
Total combined fixed charges   277     84     137     16  
Ratio of earnings to combined fixed charges (1)   1.6     2.5     0.2     5.8  
(1) Earnings were insufficient to cover combined fixed charges by $114 million for the three months ended June 30, 2004.



Exhibit 31.1

CERTIFICATION
PURSUANT TO 17 CFR 240.13a-14
PROMULGATED UNDER
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, David N. Weidman, certify that:

1.  I have reviewed this quarterly report on Form 10-Q of Celanese Corporation;
2.  Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3.  Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4.  The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and we have:
(a)  designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
(b)  [Reserved]
(c)  evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)  disclosed in this report any change in the registrant's internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.  The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
(a)  all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)  any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 12, 2005

/s/ David N. Weidman
David N. Weidman
President and Chief Executive Officer




Exhibit 31.2

CERTIFICATION
PURSUANT TO 17 CFR 240.13a-14
PROMULGATED UNDER
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2003

I, Corliss Nelson, certify that:

1.  I have reviewed this quarterly report on Form 10-Q of Celanese Corporation;
2.  Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;
3.  Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;
4.  The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and we have:
(a)  designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;
(b)  [Reserved]
(c)  evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)  disclosed in this report any change in the registrant's internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.  The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent functions):
(a)  all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)  any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 12, 2005

/s/ Corliss Nelson
Corliss Nelson
Chief Financial Officer




Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Celanese Corporation (the " Company ") on Form 10-Q for the period ending June 30, 2005 as filed with the Securities and Exchange Commission on the date hereof (the " Report "), I, David N. Weidman, President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.  The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.  The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 12, 2005

/s/ David N. Weidman
David N. Weidman
President and Chief Executive Officer




Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Celanese Corporation (the " Company ") on Form 10-Q for the period ending June 30, 2005 as filed with the Securities and Exchange Commission on the date hereof (the " Report "), I, Corliss Nelson, Executive Vice President and Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.  The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.  The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 12, 2005

/s/ Corliss Nelson
Corliss Nelson
Executive Vice President and Chief Financial Officer